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CHAPTER 1  
 
ION CHANNEL TRAFFICKING: A NEW THERAPEUTIC HORIZON FOR 
ATRIAL FIBRILLATION 
 
PREVALENCE AND TREATMENT OF ATRIAL FIBRILLATION 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting 
an estimated 2.2 million adults in the in the United States.
1
 AF is caused by the rapid and 
irregular activation of the atria by electrical sources outside the normal sinus node, and 
can be classified as paroxysmal, persistent, or long-standing persistent.
2
  The occurrence 
of atrial fibrillation increases dramatically with age, affecting less than 1% of individuals 
under age 50 to approximately 10% of individuals over age 80.
1, 3
 Importantly, over the 
past two decades the age standardized death rate (per 100,000 in the US) has increased 
from 27.6 to 69.8.
4
  Therefore, AF presents a significant increasing health risk with an 
untold burden for healthcare costs. 
The combination of inefficient atrial contraction and irregular ventricular rate can lead to 
serious complications.  AF related deaths are due primarily to the increased risk of stroke 
and heart failure.  AF is associated with a nearly 5-fold increase in the risk of embolic 
stroke with nearly one fourth of all strokes in patients over 80 attributable to AF.
5, 6
  This 
 
Part of Chapter 1 is published as Schumacher SM, Martens JR. (2010). Ion channel 
trafficking: a new therapeutic horizon for atrial fibrillation. Heart Rhythm. 
Sep;7(9):1309-15.  For copyright release, please see Appendix I.   
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increased rate of stroke is due to the rapid, uncoordinated atrial rhythm that leads to 
inefficient contraction of the atria, resulting in the pooling of blood in the atria and 
promotion of thrombo-emboli formation.  The presence or absence of several other risk 
factors significantly contributes to the risk of stroke, such as recent cardiac failure, 
hypertension, age, diabetes, or a history of stroke or transient ischemic attack (TIA).
7, 8
  
In addition to an increased risk of stroke, atrial thrombo-emboli can propagate to regions 
other than the brain, such as the kidneys, mesenteric circulation, or the heart itself where 
they may induce myocardial infarction.  AF also participates reciprocally with several 
comorbid conditions including congestive heart failure, thyrotoxic heart disease, and 
hypertension.
9
 
Current therapy for AF is aimed at rate control or rhythm control.
10
  In rate 
control, the goal is to maintain the ventricular rate within a physiological range by 
slowing atrioventricular conduction.  In rhythm control, treatment aims to restore normal 
sinus rhythm through pharmacological cardioversion or through electrical cardioversion 
or catheter ablation. Catheter ablation is considered a 2
nd
-line treatment for AF with 
published success rates of 22-85%.  Higher success rates are often seen for patients with 
paroxysmal AF.
2, 11-13
  While approximately half of these patients remain asymptomatic, 
nearly 30% require a second procedure and 10-25% require additional pharmacological 
therapy in order to maintain normal sinus rhythm post ablation therapy.
14, 15
 However, the 
long-term effectiveness of this technique remains to be fully determined.
16, 9
   
 Pharmacological cardioversion makes use of antiarrhythmic drugs targeting 
cardiovascular ion channels to achieve normal sinus rhythm control in the treatment of 
AF.
17-20
 Pharmacological cardioversion has an advantage over catheter ablation in that it 
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is not invasive, however it has been reported to be less effective.
21
  If class I or III 
antiarrhythmic agents are administered within the first 24 hours of onset of AF, the 
reported success rate is 47-84%; however, this drops sharply for AF that persists longer 
than 48 hours in that the antiarrhythmic therapy can only achieve cardioversion in 15-
30% of patients.
22
  
 
COMPOSITION OF THE ATRIAL ACTION POTENTIAL 
 Atrial action potentials result from the coordinated opening and closing of 
voltage-gated ion channels in the myocyte membrane.
23, 24
  The atrial action potential is 
initiated by rapid depolarization induced by a large inward sodium current INa through the 
cardiac-specific sodium channel Nav1.5.
23, 24
  This influx of Na
+
 constitutes phase 0 and 
depolarizes the cell from the threshold membrane potential of approximately -70mV to 
the area of +40mV.  Partial repolarization is then mediated by the transient outward K
+
 
current Ito, mediated by a combination of Kv1.2, Kv4.2, and Kv4.3.
23, 24
  Rapid 
inactivation of Ito and the activation of an inward L-type Ca
2+
 current ICa, produce the 
notch (phase 1) and plateau (phase 2) of the action potential.  Time-dependent activation 
of a series of delayed rectifier currents, the ultra-rapid IKur (Kv1.5), the rapid IKr (Kv2.1 
and Kv11.1, or hERG), and the slow IKs (Kv7.1 or KvLQT1) components, mediate 
cellular repolarization (phase 3).
23, 24
  Hyperpolarization of atrial myocytes to the resting 
membrane potential of -90 mV is then achieved through the IK1 inward rectifier current 
(Kir2.x) and the muscarinic K
+
 current IKACh (Kir3.1/3.4) (phase 4).
23, 24
  The atrial action 
potential is thus shaped by the ensemble average of these ion channels.  The balance 
between inward and outward currents during the plateau and repolarization phase of the 
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atrial action potential determines the action potential duration (APD).  APD is a measure 
of the time from depolarization to recovery of excitability and thereby determines both 
the effective refractory period (ERF) and susceptibility to reentry.     
 
ELECTRICAL AND STRUCTURAL REMODELING DURING AF 
 Atrial fibrillation is a progressive disorder wherein the duration of the arrhythmia 
advances electrical and structural adaptations that further the susceptibility of the 
myocardium to re-entrant circuits.  Electrical remodeling is evident from the decreased 
APD and depression of the plateau of the atrial action potential.  During AF, atrial 
myocytes fire at a rate of 400-600 beats per minute (bpm), compared to the resting heart 
rate of 60 bpm or a rate of 180-200 bpm during peak exercise.  Increased atrial rate leads 
to a negative metabolic balance, associated with decreased pH and Po2 and increased 
oxidative stress.  The α1c subunit of the L-type Ca2+ channel is reversibly inhibited by 
clinically relevant decreases in Po2, therefore altered oxidative state contributes to the 
~60-70% decrease in ICa observed within 24 hours of rapid atrial pacing and in permanent 
AF.
25
 In addition to an altered oxidative state, increased atrial rate leads to elevated 
intracellular Ca
2+
 levels via entry through L-type calcium channels with each beat.
26
  As 
an adaptive mechanism to decrease the threat to cell viability posed by Ca
2+
 loading, 
atrial myocytes inactivate L-type Ca
2+
 channels through voltage-dependent and Ca
2+ 
concentration-dependent mechanisms.
27
  Decreased ICa, which under normal conditions 
drives the positive plateau voltage and contributes to action potential duration, constitutes 
a portion of the electrical remodeling observed in AF.  Electrical remodeling is also 
characterized by a 50-60% decrease in the Ito and IKur components of repolarization.
25
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Such a decrease would be expected to prolong atrial APD, however these alterations are 
countered by an increase in the outward K
+
 currents IK1 and IKACh.
25
  The summation of 
these alterations in atrial currents produces the attenuated plateau phase and decreased 
APD that characterize electrical remodeling during AF.   
 Structural remodeling is first exhibited by the redistribution of heterochromatin in 
the nucleus to resemble the homogenous pattern characteristic of embryonic and neonatal 
myocytes.
28, 29
  Subsequently, myolysis and glycogen deposition are evident in a 
population of atrial myocytes that are projected to undergo apoptosis.
30
  While the 
mechanism of sarcomeric degradation has not been fully elucidated, attention has been 
drawn to the calpain class of calcium-activated neutral proteases.  Calpain activation 
provides a link between the calcium overload induced by increased atrial rate and the 
molecular changes observed during AF.  For instance, in a number of cases the decrease 
in atrial ionic current is accompanied by a decrease in channel protein, not mRNA.
30
  The 
activity of calpain in the degradation of membrane-associated as well as cytoskeletal 
proteins would disrupt excitation-contraction coupling and may significantly underlie the 
mechanisms of electrical and structural remodeling in atrial myocytes.  Effective block of 
pacing induced structural remodeling by calpain inhibitors gives further credence to this 
model.
31
  Structural remodeling may also be the result of ischemic stress and stretch-
induced adaptive and maladaptive processes in the atrial myocardium; however, these 
processes and the timeline of their involvement remain to be fully elucidated.        
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PHARMACOLOGICAL TREATMENT OF ATRIAL FIBRILLATION 
 Three main classes of antiarrhythmic drugs are indicated for the treatment of 
abnormal rhythms such as atrial fibrillation.  Class Ia, b, and c compounds block the 
inward Na
+
 current with intermediate, fast, and slow association and dissociation, 
respectively.  These compounds, including quinidine, procainamide, disopyramide, 
flecainide, and propafenone among others are used in the prevention of paroxysmal atrial 
fibrillation.  Class III compounds such as amiodarone, dronedarone, sotalol, ibutilide, 
dofetilide, and E-4031 are K
+
 channel blockers important for rhythm control in the 
treatment of AF.  Class IV Ca
2+
 channel blockers verapamil and diltiazem are used to 
prevent recurrence of paroxysmal AF and attain ventricular rate control.  Despite the 
existence of multiple antiarrhythmic drugs with varying targets for the treatment of AF, 
there is currently no drug in clinical use that does not exhibit significant negative side 
effects.  While many of these side effects are linked to non-selective block of Kv 
channels in the atrium and ventricles, others, such as amiodarone, cause hepatotoxicity, 
peripheral neuropathy, and pulmonary toxicity, among others.
32, 33
  Several compounds, 
including quinidine and flecainide, are no longer used in the clinic due to the increased 
risk for torsade de pointes associated with long-term treatment with these compounds.
18, 
32
  Class III antiarrhythmic compounds that block atrial potassium channels also exhibit 
an increased risk for pro-arrhythmia in the ventricles upon prolonged exposure of higher 
doses.
19, 32
  Therefore, a common negative side effect for antiarrhythmic drug therapy is 
proarrhythmia in the ventricles due to non-selective ion channel block and/or overlapping 
expression of ion channels in both the atria and ventricles.  
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Recently, there has been a shift in both academia and industry to target atrial 
specific currents in order to terminate AF and maintain normal sinus rhythm while 
avoiding proarrhythmic risk in the ventricles.  One of the main targets in this research 
effort is the voltage-gated potassium channel Kv1.5 that underlies the IKur current.  
Importantly, IKur is selectively reported only in the human atria
17, 20, 34, 35
 where it 
contributes to repolarization and participates in the control of action potential duration.  
In the human atria, Kv1.5 is a predominant channel mediating repolarization and 
alterations in its expression level have been demonstrated in pathophysiological states 
such as persistent and paroxysmal AF and chronic pulmonary arterial hypertension.
17, 36
  
More specifically, there is a marked reduction in Kv1.5 channel protein expression in 
these pathophysiological states,
37,38, 39
 perhaps as an endogenous compensatory 
mechanism.  Given the atrial specific expression of Kv1.5 and its known alterations in 
cardiovascular disease, it is no surprise that the development of Kv1.5-specific blockers 
has been a target of both academic and industrial research efforts for the treatment of 
AF.
32, 40, 41
  While several compounds have been developed, these antiarrhythmic drugs 
have been limited by a lack of channel or tissue selectivity, or by poor bioavailability.   
Over the past fifteen years research in both industry and academia has focused on 
developing small-molecule inhibitors of Kv1.5 for the treatment of AF.  Three different 
mechanisms have been employed, including drugs for direct pore block of the channel, 
allosteric modulation, and use-dependent open channel block, resulting in numerous 
publications and patents.
32
  Two compounds, AVE0118 and AVE1231, were bisaryls 
developed by Aventis Pharma/Sanofi-Aventis.  While these compounds were not Kv1.5-
specific, demonstrating inhibition of Kv1.5, Kv1.3, Kv2.1, and Kv4.3 with less 
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effectiveness for blocking hERG, they exhibited both atrial selectivity and efficacy and 
were developed for clinical trials.
23, 32, 42-44
  The Kv1.5 selective blocker DPO-1, 
developed by Merck, increased atrial APD without altering ventricular function, but 
failed to demonstrate sufficient oral bioavailability.
32
  The clinical development of 
several potent Kv1.5 blockers generated by Icagen was also plagued by poor 
bioavailability.
45
  Cardiome/Astellas Pharma developed vernakalant hydrochloride 
(RSD1235) as a use-dependent blocker of Kv1.5; however, its clinical efficacy was 
hampered by a potent block of Nav1.5 at resting membrane potentials.
46-49
  Therefore, 
there remains an unmet need for the development of safe new compounds with both atrial 
selectivity and clinical efficacy for the long-term treatment of AF.   
New therapeutic strategies that focus on the regulation of ion channel surface 
density are emerging from basic research at the bench (Figures 1.1 and 1.2).
50, 51
  
Traditional antiarrhythmic drugs target the ion permeability of channels; however, as 
highlighted above this approach has not yet yielded a satisfactory outcome.  There are 
two ways to decrease IKur, through a direct effect on the conductance properties 
(classically pore block) of channel subunits or through alterations in surface density of 
the protein.  The concept of drugs modulating ion conductance and/or surface density of 
channels is not new.  For example, the antiarrhythmic agents ketoconazole and fluoxetine 
have been shown to reduce hERG density by at least 50% following 48 hours of 
treatment,
52-55
 whereas pentamidine and probucol reduce cell-surface hERG without 
affecting ion conductance.
55-58
  Research into the therapeutic potential of antiarrhythmic 
drugs that alter channel trafficking has primarily focused on hERG.  Alterations in hERG 
mediated IKr, whether drug-induced or a result of the over 200 naturally occurring 
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mutations of this channel, may induce or contribute to the development of long QT 
syndrome.  In particular, long QT syndrome type II which results from retention of 
misfolded hERG in the quality control pathways of the ER.
59, 60
  Nearly 70% of these 
mutant channels can be rescued to the plasma membrane by antiarrhythmic drugs such as 
E4031.
59, 61
  These drugs likely act to stabilize misfolded protein through facilitation of 
quality control machinery in the ER such as Hsc70 and Hsp90 that have been shown to 
exist in a macromolecular complex with hERG and facilitate its maturation and export 
from the ER.
60, 62
  Arsenic trioxide, on the other hand, interferes with the hERG-
chaperone complexes thereby decreasing surface channel.
63
  Thus far research has 
focused primarily on hERG folding and maturation with little investigation into the 
molecular mechanisms regulating anterograde trafficking from the ER to the plasma 
membrane.  In addition to interfering with hERG trafficking through inhibition of hERG-
chaperon complexes, arsenic trioxide has been demonstrated to increase cardiac calcium 
currents and IK-ATP via different cellular processes.
63, 64
  Researchers have also discovered 
that oxidative stress decreases forward connexin trafficking by disrupting microtubule 
association of EB1.
65
  Together, these studies give credence to the idea that 
antiarrhythmic drugs may be developed to manipulate specific ion channel trafficking 
pathways as a novel therapeutic approach for treating cardiac arrhythmias.   
 
GENERAL TRAFFICKING MECHANISMS 
The steady-state cell surface density of proteins is determined by the balance 
between the anterograde and retrograde trafficking pathways.  Anterograde trafficking 
ensues only after proper synthesis and processing in the endoplasmic reticulum and golgi, 
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including quality control mechanisms, glycosylation, and post-translation modification 
(Figure 1.1).
66
  Retrograde movement initiates with endocytosis after which internalized 
proteins can follow multiple routes to different intracellular fates (Figure 1.1).
67
  One 
well-recognized fate is the targeting of internalized proteins to lysosomes or proteasomes 
followed by degradation (Figure 1.1).  Alternatively, trafficking through recycling 
endosomes allows proteins to return to the plasma membrane and protects them from 
degradation (Figure 1.1).
68
  Sorting at early endosomes to Rab-GTPase specific 
compartments is now established as an important event determining the intracellular fate 
of internalized proteins.
69-71
 Another important component of the endocytic machinery 
regulating protein surface levels is the coordinated movement of molecular motors.  In 
general, protein trafficking is highly coordinated between long-range events, involving 
the microtubule-based kinesin and dynein motors, and short-range events using 
unconventional myosin motors.
72-75
  There is a significant and growing body of literature 
about ion channel trafficking from synthesis to sorting to degradation in multiple tissues 
and cells systems that has been reviewed previously.
76-80
  Our discussion will center 
mainly on recent work focused on the acute modulation of ion channel density at the 
plasma membrane in the heart where relatively little is known about protein trafficking.  
 
KV1.5 CHANNEL TRAFFICKING IN ATRIAL MYOCYTES 
While the precise mechanisms regulating plasma membrane localization and 
targeting of Kv1.5 in atrial myocytes have not been fully elucidated, several key 
components and steps are now known.  The formation of functional Kv1.5 begins in the 
endoplasmic reticulum (ER) where tertiary folding is coupled to formation of the 
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quaternary structure through tetramerization of the T1 domain in the amino terminus of 
this channel.
81
  The first transmembrane segment (S1) of Kv1.5 has also been implicated 
in the co-assembly of homo- and heterotetrameric K
+
 channels.
82
  ER to Golgi trafficking 
of Kv1.5 is facilitated by a “VXXSN” forward trafficking signal located in the C-
terminus of the channel.
83, 84
  In addition to forward trafficking signals, ER to Golgi 
trafficking of many Kv channels is dependent upon interactions with accessory subunits 
such as the KvBeta subunits, K
+
 channel associated protein KChAP, and the K
+
 channel 
interacting protein KChIP.
76
  Despite interaction with the N-terminus of Kv1.5, KChAP 
does not alter the current properties or current density of the channel and therefore is not 
necessary for plasma membrane trafficking.
85
   
In addition to protein folding/assembly and subunit composition, post-
translational modification can play a crucial role in determining the plasma membrane 
levels of functional Kv1.5.
86-95
  Kv1.5 contains putative PKC and PKA phosphorylation 
sites; however, direct PKC- or PKA-mediated phosphorylation of channel has not been 
demonstrated.  Association of Src tyrosine kinase with two, repeated Src homology 3 
(SH3) domains in the N-terminus of Kv1.5 leads to direct phosphorylation the channel 
and a significant decrease in current density.
96
  N-linked glycosylation of human Kv1.5 at 
serine 292 is important for determining the voltage-dependence of activation and current 
density of the channel.
97, 98
  In addition to phosphorylation and glycosylation, Kv1.5 has 
been shown to undergo S-acylation.
87
  S-acylation occurs via the reversible linkage of 
fatty acids to target proteins through a thioester bond to a cysteine residue.  Kv1.5 
contains two N- and four C-terminal cysteine residues that can undergo S-acylation, and 
pharmacological inhibition of this modification results in the intracellular accumulation 
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and proteasomal degradation of Kv1.5.
87
  As S-acylation was found to occur prior to 
glycosylation in the biosynthetic pathway of Kv1.5, and pharmacological intervention led 
to a significant decrease in current density, this post-translational modification may play 
an important role in the cell surface trafficking of properly assembled Kv1.5.
87
   
At the plasma membrane, localization to specific membrane microdomains and 
association with scaffolding proteins into macromolecular signaling complexes may 
contribute to the stability and biological function of Kv1.5.
98-104
  Golgi to plasma 
membrane trafficking of Kv1.5 involves targeting to calveolar-lipid raft membrane 
microdomains.
102
  Disruption of lipid rafts through depletion of their component 
cholesterol and sphingolipids alters the biophysical properties of the channel.  While the 
Kv4.2 subunit that is not targeted to lipid raft microdomains was unaltered, depletion led 
to a hyperpolarizing shift in both the voltage dependence of activation and inactivation of 
Kv1.5.
105
  Targeting of Kv1.5 to lipid rafts involves interactions with caveolin-1, as 
evidenced by the depolarizing shift in the voltage dependence of activation and 
inactivation observed upon its expression.
105
  Cell surface levels of Kv1.5 are also 
determined through interaction with the PDZ domain-containing proteins SAP97, alpha-
actinin-2, and PSD95.
98, 99, 101, 104, 106-109
  SAP97, a membrane associated guanylate kinase 
(MAGUK), is localized in lipid rafts and contains numerous protein interaction motifs 
including SHK and guanylate kinase (GUK)-like domains that may serve as nucleation 
sites for the formation of macromolecular signaling complexes for the regulation of 
Kv1.5.
98
  PSD95, which associates with Kv1.5 via a T1/core region of the channel, may 
also play a critical role in the localization of Kv1.5 to specific membrane microdomains 
as evidenced by its role in the clustering of the NMDA receptor and Kv1.4 in neurons.
109
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Alpha-actinin-2, a member of the spectrin gene superfamily, also interacts with Kv1.5 
through the T1/core region of the channel and direct knockdown of alpha-actinin-2 via 
antisense oligonucleotides alters channel current density.
94, 103, 110
     
Despite association with scaffolding proteins, Kv1.5 has been shown to undergo 
dynamic trafficking at the plasma membrane through constitutive internalization and 
recycling.
111
  Internalization of Kv1.5 occurs via a dynein-mediated, microtubule 
dependent pathway to perinuclear endosomal compartments with a t1/2 of approximately 
11 minutes at physiological temperature.
111, 112
  Following internalization, sorting of 
Kv1.5 into specific, rab-dependent endocytic compartments determines the intracellular 
fate of the channel.  Specifically, association of Kv1.5 with Rab 4- or Rab 11-containing 
endocytic vesicles is associated with recycling of the channel back to the plasma 
membrane, whereas association with Rab 7-containing vesicles denotes channel 
degradation.
111-113
  In addition, ubiquitin modification of Kv1.5 has been described in 
agreement with data implicating the proteasome in channel degradation.
50, 87, 114-116
  As 
the molecular machinery and endogenous regulatory mechanisms controlling Kv1.5 
surface density begin to emerge, one new therapeutic horizon is the extrinsic 
manipulation of Kv1.5 surface levels (Figure 1.2). 
 
SUMMARY 
Atrial fibrillation (AF) is a common cardiac arrhythmia with potentially life-
threatening complications.  Drug therapies for treatment of AF that seek long-term 
maintenance of normal sinus rhythm remain elusive due in large part to proarrhythmic 
ventricular actions.  Kv1.5, which underlies the atrial specific IKur current, is a major 
14 
  
focus of research efforts seeking new therapeutic strategies and targets.  Difficulty in 
attaining clinical efficacy and safety through atrial selective block and increasing 
evidence of pleiotropic effects of pharmacological agents has led to the emergence of 
channel trafficking as a novel therapeutic target for the treatment of AF.  The underlying 
mechanism of these pleiotropic effects and the molecular machinery and endogenous 
regulatory mechanisms selectively controlling Kv1.5 surface density must be elucidated 
to determine the therapeutic potential of extrinsic manipulation of Kv1.5 surface levels. 
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Each arrow represents a regulatory step in the trafficking of membrane proteins that 
could serve as a potential therapeutic target for modulating steady-state cells surface 
levels of ion channels.  The left half of this figure represents an area where much work 
has been done in the hERG field for the treatment of LQTS and other arrhythmias.  The 
right half represents and exciting developing field for the regulation of Kv1.5 membrane 
levels in the treatment of atrial fibrillation.  Endoplasmic Reticulum (ER); Recycling 
Endosome (RE); Late Endosome (LE). 
 
 
Figure 1.1 Potential therapeutic intervention points in the trafficking of membrane. 
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(A) Drug-induced internalization is specific to the atrial potassium channel Kv1.5.  (B) 
Kv1.5 specific internalization results in a decrease in IKur density.  (C) Decreased IKur may 
result in an increase in atrial, not ventricular, action potential duration.  (D) Increased 
atrial action potential duration may terminate atrial fibrillation and restore normal sinus 
node rhythm control. 
Figure 1.2 Antiarrhythmic drug-induced internalization of atrial specific Kv1.5 as a 
novel therapeutic target for AF. 
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CHAPTER 2  
 
ANTIARRHYTHMIC DRUG-INDUCED INTERNALIZATION OF THE ATRIAL 
SPECIFIC K+ CHANNEL, KV1.5 
 
ABSTRACT 
Conventional antiarrhythmic drugs target the ion permeability of channels, but increasing 
evidence suggests that functional
 
ion channel density can also be modified 
pharmacologically.  Kv1.5 mediates the ultrarapid potassium current (IKur) that
 
controls 
atrial action potential duration.  Given the atrial specific expression of Kv1.5 and its 
alterations in human atrial fibrillation, significant effort has been made to identify novel 
channel blockers.  In this study, treatment of HL-1 atrial myocytes expressing Kv1.5-
GFP with the class I antiarrhythmic agent quinidine, resulted in a dose-, and temperature-
dependent internalization of Kv1.5, concomitant with channel block. This quinidine-
induced channel internalization was confirmed in acutely dissociated neonatal myocytes.  
Channel internalization was subunit-dependent, activity-independent, stereospecific, and 
blocked by pharmacologic disruption of the endocytic machinery.  Pore block and 
channel internalization partially overlap in the structural requirements for drug binding. 
 
Chapter 2 is published as Schumacher SM, McEwen DP, Zhang L, Arendt KL, Van 
Genderen KM, Martens JR. (2009). Antiarrhythmic drug-induced internalization of the 
atrial-specific k+ channel kv1.5. Circ Res. Jun 19;104(12):1390-8.  For copyright release, 
please see Appendix I.   
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Surprisingly, quinidine-induced endocytosis was calcium-dependent and therefore 
unrecognized by previous biophysical studies focused on isolating channel-drug 
interactions. Importantly, while acute quinidine-induced internalization was reversible, 
chronic treatment led to channel degradation.  Together, these data reveal a novel 
mechanism of antiarrhythmic drug action and highlight the possibility for new agents that 
selectively modulate the stability of channel protein in the membrane as an approach for 
treating cardiac arrhythmias. 
 
INTRODUCTION 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a major risk 
factor for increased stroke, heart failure, and cardiovascular morbidity.  The preferred 
therapy for AF is sustained sinus rhythm control; however, the efficacy of currently-used 
antiarrhythmic drugs is diminished by adverse side effects resulting from a lack of ion 
channel selectivity and nonspecific ventricular activity 
117, 118
.  Due to the frequency of 
AF and its associated morbidity, development of atrial-specific therapies is a major focus 
of both industrial and academic research efforts 
40, 41
.  
Kv1.5 (KCNA5) has emerged as a promising pharmacologic target for treatment 
of AF.  In humans, Kv1.5 is selectively expressed in atrial myocytes where it mediates 
the ultrarapid delayed rectifier current (IKur) that
 
contributes to cellular repolarization and 
controls action potential (AP) duration 
67, 119
. Although significant effort has been made 
to identify novel blockers of Kv1.5, compounds with both atrial selectivity and clinical 
efficacy remain elusive and highlight the need for new potential therapeutic strategies or 
targets.    
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Conventional antiarrhythmic drugs generally target the ion permeability of 
channels. Increasing evidence, however, suggests that functional ion channel density can 
be modified pharmacologically in that a drug may both directly block an ion channel and 
indirectly disrupt normal protein trafficking 
51
.  In fact, one report shows that nearly half 
of hERG channel pore-blockers tested also decrease anterograde delivery of the channel 
to the cell surface 
120
.  In addition, two reported cases of disrupted protein trafficking 
leading to drug-induced prolongation of the cardiac AP highlight that this pleiotropic 
drug action can modulate cardiac excitability 
63, 64
.  Research into the therapeutic value 
for antiarrhythmic agents that affect channel trafficking has focused almost exclusively 
on hERG channel blockers that stabilize misfolded channels and rescue hERG trafficking 
mutants.  To date, no studies have addressed the potential properties of antiarrhythmic 
drugs to acutely modulate surface density of functional channels that exist on the cardiac 
myocyte membrane.  Here we report, for the first time, a novel paradigm for 
antiarrhythmic pharmacology in the control of the cell surface stability of Kv1.5 in atrial 
myocytes and present a new mechanism for the inhibition of ion current through drug-
stimulated endocytosis of channel protein.   
 
RESULTS    
The Antiarrhythmic Drug, Quinidine, Stimulates Rapid Kv1.5 Internalization in 
HL-1 Atrial Myocytes.   
Multiple antiarrhythmic drugs have been shown to inhibit Kv1.5, including the class I 
antiarrhythmic drug quinidine, which, like many Kv channel inhibitors, causes an 
activity-dependent, open-channel block of Kv1.5 (Figure 2.2A).  The present study was 
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designed to investigate the potential pleiotropic effects of antiarrhythmic agents on Kv1.5 
using this well characterized drug as a prototype 
121
.  Our studies were initiated in the 
HL-1 immortalized mouse atrial myocyte cell line in which we previously demonstrated 
that Kv1.5 undergoes constitutive internalization and recycling to maintain steady-state 
ion channel surface levels 
111
.  Using an extracellular GFP epitope-tagged Kv1.5 
construct that mimicked wild type channel function, we discovered that quinidine 
triggered Kv1.5 internalization concomitant with block of channel current (Figure 2.1A, 
Figure 2.2).  Exposure to increasing concentrations of quinidine stimulated a dose-
dependent increase in internalized Kv1.5 with a corresponding loss of surface protein 
(Figure 2.1B). This quinidine-induced internalization culminated in an 80 ± 13% (n = 
143; p < 0.001) increase over constitutive channel endocytosis at 100 μmol/L quinidine 
(EC50 ≈ 1 mol/L).  Quinidine-induced internalization of Kv1.5 was rapid and achieved a 
maximum within 10 min of treatment (Figure 2.2E).  Electrophysiology experiments 
confirmed that 10 min quinidine treatment represents steady-state channel block (Figure 
2.2D).  Together, these data indicate that the rate-limiting step for this process is 
equilibration of quinidine across the cell membrane.  Following 10 min vehicle treatment, 
the level of internalized Kv1.5 is minimal and consistent with constitutive endocytosis as 
previously reported
111
 (Figure 2.1A). Importantly, at the 10 min time point quinidine-
stimulated internalization was statistically greater compared to control (p <0.001) and 
could be reliably separated from constitutive endocytosis and was therefore used, unless 
otherwise stated, in our later studies.    
We also measured a temperature-dependence for the quinidine-induced 
internalization of Kv1.5 (Figure 2.1C).  The drug-induced internalization was greater than 
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two-fold higher at the physiological temperature of 37˚C compared to room temperature 
(80 ± 13% (n = 143) at 37˚C versus 45 ± 11% (n = 130) at 25˚C; p < 0.001).  Importantly, 
the EC50 values were identical and only the extent of quinidine-induced internalization 
was temperature-dependent.  It is noteworthy, that previous biophysical studies 
measuring pore-block with quinidine were performed at room temperature where the 
effects of internalization would be inadvertently reduced.   
One potential concern regarding our internalization assay is that the treatment 
with primary antibody prior to initiating internalization could cause an antibody-induced 
artifact.  To negate this possibility we generated a Kv1.5 construct in which GFP was 
replaced with pHluorin, a GFP variant whose fluorescent properties are sensitive to the 
pH of the immediate environment 
122
.  Internalization of cell surface channel to 
endosomes with acidic pH quenches the pHluorin signal as measured by reduced 
fluorescence.  Internalized channel was protected from photobleach and its perinuclear 
localization revealed by neutralization with ammonium chloride (Figure 2.3B).  Using 
live-cell imaging of HL-1 cells expressing Kv1.5-pHluorin, we found no difference in the 
time course, extent, or subcellular localization of quinidine-induced internalized channel 
compared to results from our antibody-labeling internalization assay (Figure 2.3A).  
Together, these results suggest that antiarrhythmic drugs may modulate retrograde 
trafficking of Kv1.5 as a mechanism contributing to their inhibition of outward K
+
 
current.  
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Constitutive and Quinidine-induced Internalization of Kv1.5 is Conserved in Native 
Dissociated Mouse Myocytes.  
We investigated the validity of the quinidine effect in native dissociated mouse myocytes.  
The live-cell internalization assay was performed on acutely dissociated neonatal mouse 
myocytes expressing Kv1.5-GFP to probe for alterations in Kv1.5 distribution upon 
quinidine treatment.  Using this technique, we found levels of constitutive and quinidine-
induced channel internalization similar to those observed in the HL-1 model (Figure 
2.4A).  This drug-induced internalization culminated in an 84 ± 19% (n = 45) (p < 0.001) 
increase over constitutive channel endocytosis at 100 μmol/L quinidine (n = 52), with a 
corresponding decrease in surface levels (Figure 2.4B).  These data confirm that the 
endogenous machinery and mechanistic requirements for constitutive and quinidine-
induced Kv1.5 internalization are conserved in native cardiac tissue. 
 
Specificity of Quinidine-induced Internalization.  
We investigated the subunit specificity by measuring quinidine effects on internalization 
of two other prominent cardiovascular potassium channels, Kv4.2 and Kv2.1, expressed 
in HL-1 cells.  Although ion permeability of both channels is blocked by quinidine (IC50 
of 10 μmol/L and 20  μmol/L quinidine, respectively) 123, 124, neither Kv4.2 nor Kv2.1 
internalized in response to any drug concentration tested over the time course studied 
(Figure 2.5A, Figure 2.6 and 2.7).  Despite differences in surface levels of channel, the 
surface to total protein ratio for each subunit did not differ from Kv1.5 (Figure 2.6A and 
2.7B), indicating that the absence of quinidine-induced internalization is not due to a lack 
of surface channel.  In addition, Kv4.2 was found to undergo constitutive endocytosis 
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similar to Kv1.5 (Figure 2.6B), indicating that detection of internalized channels is not 
problematic at the low expression levels observed with Kv4.2 and that the lack of 
quinidine-induced internalization is not due to an inability of the channel to access the 
endocytic pathway.  Interestingly, we observed that Kv2.1 was sequestered in plaque-like 
clusters in agreement with previous reports in native atrial, but not ventricular, myocytes 
125
.  This finding further validates that the molecular machinery for channel localization is 
intact in the HL-1 atrial myocyte model (Figure 2.7A).  Together, these data demonstrate 
a subunit-dependence for the quinidine-induced internalization of Kv1.5.   
Quinidine-induced internalization occurred at resting membrane potentials 
suggesting that the drug-induced trafficking effects may be conductance-independent.  To 
address this possibility, we measured internalization of the pore-dead mutant Kv1.5-
W472F, which efficiently traffics to the myocyte membrane but is incapable of 
conducting current 
126
. For both the mutant and wild-type controls, the quinidine-induced 
internalization resulted in an approximately 90 ± 20% (n = 90) (p < 0.001) increase over 
constitutive endocytosis, with no difference observed in the EC50 value (Figure 2.5B). 
These data confirm that the quinidine-induced internalization of Kv1.5 is independent of 
channel ion conductance.  
 
Structural Requirements of Quinidine-induced Internalization.   
To further examine specificity and gain possible insight into the pharmacophore 
responsible for drug-induced internalization of Kv1.5, we tested quinine, the 
diastereomer of quinidine that also causes a dose-dependent block of Kv1.5 current 
127, 
128
. We found that, contrary to quinidine, a maximal concentration of quinine was not 
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able to enhance Kv1.5 internalization above constitutive levels (Figure 2.5C). Quinine 
was, however, capable of inducing significant, dose-dependent block of Kv1.5 that was 
reversible upon drug washout (Figure 2.8).  The inability of quinine to induce channel 
internalization, despite effective pore block, demonstrates that quinidine-induced 
internalization of Kv1.5 is stereospecific.   
The subunit-dependence and stereospecificity of quinidine-induced internalization 
of Kv1.5 indicates a reliance of this internalization on the structure of the channel.  To 
determine whether the protein structural requirements for quinidine-induced 
internalization were the same as those for pore block, we used the live-cell internalization 
assay to investigate the effect of quinidine on several mutants of Kv1.5.  Kv1.5-T480A 
contains a single point mutation in the putative binding site for quinidine, resulting in a 
greater than 90% reduction in sensitivity to open-channel blockers of Kv1.5 
42, 129
. We 
found that, as with pore block, quinidine-induced internalization was abolished with the 
T480A mutation (Figure 2.9A). To further probe the amino acid requirements, we 
expanded our alanine-scanning mutagenesis to include three additional amino acid 
residues (Ile-508, Leu-510,
 
and Val-512) which are considered part of the highly 
conserved antiarrhythmic drug binding site within Kv channels 
42, 129
. We found that as 
reported for channel block, quinidine-induced internalization was abolished by the 
Kv1.5-I508A mutation. Surprisingly, however, unlike channel block, internalization was 
near wild-type for both Kv1.5-L510A and Kv1.5-V512A (Figure 2.9B).  Additionally, we 
tested Kv1.5-P532L, a naturally occurring mutation reported to cause a significant 
rightward shift in the dose response curve for quinidine block of channel current 
130
.  We 
observed a similar decrease in sensitivity to quinidine-induced channel internalization 
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with a shift in the EC50 from approximately 1 μmol/L for wild-type channel to 104 
μmol/L for Kv1.5-P532L (n > 90) (Figure 2.9C).  These data show that quinidine is 
acting directly on the channel and not through off-target effects that may influence 
trafficking.  Importantly, these data also indicate that antiarrhythmic drugs may both 
block channel current and disrupt protein endocytosis concurrently to alter the functional 
ion channel density in the cell membrane and that these two effects share partial overlap 
in the structural requirements for drug binding, but the necessary amino acids are not 
identical.    
 
Channel Internalization is Prevented by Disruption of Endocytic Machinery.   
Our previous studies demonstrated that constitutive Kv1.5 internalization occurs via a 
microtubule-dependent, dynein-mediated endocytic pathway 
111
.  To further address 
specificity and determine if quinidine-induced internalization shares a similar 
mechanism, we used pharmacological and dominant-negative methods to disrupt the 
endocytic machinery prior to measuring quinidine-stimulated Kv1.5 internalization.  
Dynasore, a cell-permeant, potent small molecule inhibitor of dynamin, prevents the 
budding and pinching off of endocytic vesicles 
131, 132
, and has been used in neurons to 
block synaptic vesicle endocytosis 
133
.  Acute pretreatment with this pharmacologic 
inhibitor abolished quinidine-induced internalization of Kv1.5 in atrial myocytes (Figure 
2.10A).  We also observed a nearly 100% increase in surface levels of Kv1.5 over 
untreated controls indicating that Dynasore prevents constitutive endocytosis of the 
channel (Figure 2.10B, C).  Another major component of the endocytic machinery is the 
microtubule-dependent retrograde motor complex consisting of dynein and dynactin 
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connected by the adaptor protein p50-dynamitin 
134, 135
.  Previously, we and others 
reported that overexpression of p50-dynamitin, which results in the uncoupling of the 
retrograde motor complex from its cargo to disrupt retrograde trafficking, blocked 
constitutive Kv1.5 endocytosis 
111, 112
.  In our current studies, we found that p50-
dynamitin overexpression also blocked quinidine-induced internalization with a 
corresponding increase in surface levels similar to the inhibition measured with Dynasore 
(Figure 2.11).  These data indicate that quinidine-induced internalization of Kv1.5 occurs 
via a microtubule-dependent, dynein-mediated pathway as previously demonstrated for 
constitutive endocytosis.   
Quinidine-induced Internalization is Calcium-dependent.  
To further investigate the mechanisms controlling quinidine-induced internalization, we 
tested the calcium dependence of this process.  The biophysical properties of Kv1.5 pore-
block by quinidine have been previously characterized 
121, 128
.  Our survey of the 
literature revealed that all of these electrophysiological studies included a calcium-
chelating agent in the pipette solution to isolate the drug-channel interaction.  Since 
several intracellular trafficking pathways are known to be calcium-dependent 
136
, 
inclusion of a calcium-chelating agent could inhibit the endogenous or drug-induced 
trafficking pathways.  To investigate this possibility, we performed whole-cell patch-
clamp recordings on cells stably expressing Kv1.5 both in the presence and absence of 
the calcium-chelating agent, BAPTA, in the pipette solution.  In response to a single 
depolarizing pulse from -80mV to +60mV, perfusion of cells for 10 min with 6 μmol/L 
quinidine reduced the peak current and accelerated the time course of inactivation under 
both conditions.  Surprisingly, however, exclusion of BAPTA resulted in a much larger 
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effect on peak current and revealed a significant calcium-dependent decrease.  This 
decrease in Kv1.5 current in the absence of BAPTA was observed over a range of 
voltages (Figure 2.13). Further, in the absence of BAPTA in the pipette solution, the 
dose-response for quinidine was significantly leftward shifted with a 3-fold decrease in 
the IC50 (IC50 = 13 μmol/L + BAPTA and 3.5 μmol/L – BAPTA) (n = 5) (Figure 2.12B).  
Conversely, this calcium-dependent decrease in current density did not occur with 20 
μmol/L quinine, the diastereomer of quinidine (Figure 2.14). This is in agreement with 
our finding that quinine did not induce channel internalization.  Together, these data 
provide functional evidence for quinidine-induced channel internalization through a 
calcium-dependent mechanism.  
To determine if these functional measurements are supported by fluorescence 
imaging data, we measured the quinidine-induced internalization of Kv1.5 in the 
presence of the cell-permeant compound BAPTA-AM to chelate intracellular calcium.  
Using this method, pretreatment with 10 μmol/L BAPTA-AM completely blocked 
quinidine-induced internalization of Kv1.5 with a corresponding increase in surface 
levels (Figure 2.12C).  These results were nearly identical to those determined after 
endocytic disruption with Dynasore and p-50 dynamitin (Figure 2.10C and Figure 2.11).  
Together, these data demonstrate that quinidine-induced internalization is calcium-
dependent and therefore unrecognized by previous biophysical studies focused on 
isolating channel-drug interactions.   
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Differential Effects of Acute Versus Chronic Treatment with Quinidine.   
Previously we reported that, following constitutive internalization, a population of Kv1.5 
originating on the atrial myocyte cell surface recycled back to the plasma membrane 
111
.  
Electrophysiologically, we showed that quinidine-induced block of Kv1.5 current is 
reversible upon drug washout.  Upon quinidine-stimulation, internalized Kv1.5 also co-
localized with the early endosomal marker EEA1 (data not shown).  Therefore, we 
measured the intracellular fate of the quinidine-induced, internalized Kv1.5 upon drug 
washout.  Using a modified form of the recycling assay developed previously within our 
laboratory, and HL-1 cells transiently expressing Kv1.5-GFP, we found that a population 
of Kv1.5 undergoing quinidine-induced internalization recycled back to the plasma 
membrane with the same time constant as constitutive recycling ( =29.06 min and 25.72 
min, respectively) (Figure 2.15A).  This channel recycling also occurred on a time scale 
nearly identical to recovery from current block 
121
.  This suggests that the rate limiting 
step for recovery of Kv1.5 current is not quinidine dissociation from channel and 
indicates that quinidine is acting on the internalization pathway and not on the recycling 
pathway.  Recycled channel levels 60 minutes post quinidine-induced internalization 
were approximately 33% greater than those post constitutive endocytosis (Figure 2.16A).  
This difference is most likely attributed to an increased pool of internalized Kv1.5 
available for recycling following drug treatment.  To clarify this difference, we labeled 
surface channel 60 minutes post washout of both constitutive endocytosis and quinidine-
induced internalization, and found no difference in steady-state cell surface levels of 
channel (Figure 2.16B).  Importantly, over the time course studied, we detected no loss in 
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total protein, as measured by total GFP fluorescence, indicating that there was no 
detectable channel degradation (Figure 2.15A inset).   
In a clinical setting, however, antiarrhythmic agents are administered chronically, 
over long periods of time 
18, 137-139
.  To investigate a potential long-lasting effect of 
chronic quinidine on the dynamic trafficking of Kv1.5, we treated HL-1 cells stably 
expressing Kv1.5 with a clinically relevant concentration of 10 μmol/L quinidine.  Total 
Kv1.5 protein levels were assessed by Western blot at 0, 12, and 48 hours of quinidine 
exposure, and were reduced by 13% and 43% at 12 and 48 hours, respectively (n = 9; n = 
21, respectively; p < 0.01 at 48hr) (Figure 2.15B).  Immunocytochemistry revealed a 
corresponding decrease in surface Kv1.5 (Figure 2.16C) that was significant at 12 hours 
of quinidine treatment.  As expected, these data indicate that Kv1.5 internalization 
precedes the loss of total channel protein and likely reflects a delay in the cellular time 
course for the onset of protein degradation.  Importantly, the decrease in total Kv1.5 
protein at 48 hours of chronic quinidine treatment was blocked by the mild proteasome 
inhibitor, ALLN, but not the lysosomal inhibitor, leupeptin (Figure 2.15C).  Together, 
these data reveal that acute quinidine treatment leads to channel internalization that is 
reversible upon drug washout, whereas chronic quinidine treatment leads to channel 
degradation. 
 
DISCUSSION 
 Recently, we demonstrated an unexpected dynamic trafficking of Kv1.5 at the 
atrial myocyte plasma membrane and a role for recycling in the maintenance of steady-
state ion channel surface levels 
111
.  Here, we report a previously unrecognized 
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mechanism of antiarrhythmic drug action in the acute modulation of surface channel 
density.  Using quinidine, an antiarrhythmic agent which has both class Ia actions 
140, 141
 
and class III actions in mammalian atrium and ventricle, we demonstrate that channel 
blockers can both inhibit ion conductance and regulate the stability of the channel protein 
within the membrane.  These pleiotropic actions, which may be independent, have 
important implications for antiarrhythmic drug therapy as well as drug safety testing.   
The manipulation of ion channel trafficking pathways, particularly those that 
target functional channels existing in the myocyte membrane represents an alternative 
and potentially beneficial new therapeutic strategy.  There is a clear need for the 
development of new, longer-term antiarrhythmic drugs to successfully maintain normal 
atrial sinus rhythm without risking the occurrence of potentially life-threatening, 
proarrhythmic ventricular side effects.  The inhibition of Ito current, through block of 
Kv4.2/Kv4.3 channels in the atria and ventricle, is a frequent side effect of putative 
Kv1.5-selective agents.  Our data demonstrate that quinidine-induced internalization of 
Kv1.5 is dose-, and temperature-dependent and, although it inhibited current, did not 
stimulate internalization of Kv2.1 or Kv4.2 channels.  Ultimately, the development of 
new compounds and their efficacy to selectively modulate trafficking pathways is 
dependent on the ability to separate the pleiotropic actions and to isolate the 
pharmacophore responsible for block and/or internalization.  In the current study, several 
lines of evidence indicate that these two processes may be separable.  For instance, 
quinidine-induced internalization was voltage- and activity-independent in that it occurs 
at resting membrane potentials during immunocytochemistry and when cells are voltage 
clamped at -80 mV during electrophysiology measurements (Figures 2.1 and 2.12). In 
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contrast, open channel block of Kv1.5 was voltage- and activity-dependent (Figure 2.2).  
In addition, there are several pieces of data in this study in which pore block occurred 
without channel internalization. As mentioned above, both Kv4.2 and Kv2.1 exhibit 
significant quinidine-mediated current block, however neither underwent drug-induced 
internalization, despite constitutive endocytosis of Kv4.2 nearly identical to Kv1.5 
(Figure 2.6).  Importantly, drug-induced internalization of Kv1.5 was stereospecific in 
that quinine, the diastereomer of quinidine, caused current block of Kv1.5, but was 
incapable of inducing channel internalization even at a maximal dose (Figure 2.5).  
Interestingly, alanine-scanning mutagenesis of the conserved Kv channel drug binding 
site showed that not all residues were conserved for both pore block and channel 
internalization (Figure 2.9).  To facilitate the development of new antiarrhythmic drugs 
that selectively modulate channel density, future detailed structure-activity studies are 
required to identify the essential features within the channel and as part of the drug 
molecule responsible for quinidine’s multiple activities.  The mechanism of drug-induced 
internalization most likely involves a conformational change in the channel protein; 
however, not all of the mutagenesis results in this study can be reconciled with the model 
that drug block and drug-induced internalization can be separated. For example, if one 
considers the effects of the T480A mutation, which occurs within the pore helix and 
diminishes both block and internalization, compared to our results that drug-induced 
internalization occurs when cells are clamped at -80 mV, it is difficult to envision how 
quinidine can reach a binding site in the conduction pathway to initiate internalization if 
the cytoplasmic gate of Kv1.5 is firmly closed.  An alternative strategy is the 
identification of the molecular machinery and further elucidation of the proteins involved 
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in channel targeting, such as the dynein motor complex (Figure 2.11), which may reveal 
novel, selective auxiliary therapeutic targets. Nonetheless, this study highlights the 
potential for development of new agents which can selectively affect either ion 
conduction and/or ion channel trafficking pathways as a new means to gain therapeutic 
specificity.  
The potential for drugs to modulate surface density also raises important issues 
for drug safety screening.  It is well known that non-antiarrhythmic drugs can have 
proarrhythmic liabilities through the off-target inhibition of ion channels in the heart.  
This issue has received considerable attention from pharmaceutical companies and 
regulatory agencies that now mandate cardiac ion channel testing as part of drug safety 
profiling.  Attention to the potential problem of non-antiarrhythmic drugs affecting both 
pore-block and channel trafficking originated with work related to the hERG channel 
51
.  
Data presented in this manuscript advance this concept to include the atrial specific target 
Kv1.5 and extend this concern to the acute regulation of surface density.  Current safety 
screens focus almost entirely on a drug’s capacity to block ion conductance.  The 
calcium-dependence of quinidine-induced internalization of Kv1.5 is important when 
considering the in vivo effects of this drug and most likely many others.  Our results 
demonstrate that use of compounds that deplete free intracellular calcium block a major 
component of quinidine action on Kv1.5.  This calcium-dependent component is 
responsible for a significant fraction of the quinidine-mediated decrease in current 
density and can explain the leftward shift in the EC50 for quinidine from 13 μmol/L in the 
biophysical studies including BAPTA to 3.5 μmol/L in the absence of BAPTA (Figure 
2.12B). However, it is important to note that the free calcium concentration is likely very 
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high in our electrophysiological experiments performed in the absence of any calcium 
buffer, while large changes in free calcium are not expected in immunocytochemistry 
experiments.  In addition, the two experiments were performed at different temperatures; 
therefore, the two conditions may not be identical. It is also possible that what is marked 
as calcium-dependent channel internalization (Figure 2.12A) is a mix of fast block and 
channel internalization. However, separation of these two mechanisms is complicated by 
our finding that the rate-limiting step for the onset of drug action is equilibration across 
the membrane and both block and internalization recover upon washout of the drug.  
Nevertheless, this work implies that antiarrhythmic agents such as quinidine, which affect 
channel trafficking pathways, may show greater efficacy and potency in the in vivo 
condition where calcium-dependent pathways are uninhibited.  Screens for pore block 
may simply miss channel trafficking effects and dramatically underestimate drug actions.   
Another issue that may compound these concerns is the acute versus chronic 
effects of altering channel surface density.  Our results show that chronic quinidine 
treatment results in a significant decrease in Kv1.5 channel protein by diverting channel 
from a recycling to degradation pathway.  Recent work suggests that a fraction of 
internalized Kv1.5 enters proteasomal compartments 
87
.  This is supported by data in this 
manuscript showing that inhibition of the proteasomal degradation machinery prevented 
the chronic quinidine-induced decrease in total Kv1.5.   The time course of recovery from 
this repression may precipitate drug-withdrawal side effects while long-term suppression 
of channel expression may contribute to remodeling of heart tissue.  The alternative is 
that chronic suppression may overcome current antiarrhythmic drug limitations of acute 
cardioversion and result in the benefit of maintained rhythm control.  Nonetheless, 
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together these data give further credence to concerns regarding the comprehensiveness of 
current ion channel drug safety tests.   
In summary, this report reveals a novel mechanism of antiarrhythmic drug action 
in the modulation of surface channel density.  Results of this study highlight the 
possibility for development of new agents that selectively modulate ion conduction 
and/or the stability of channel protein in the membrane as an alternative or 
complementary strategy for treating atrial fibrillation and other potential cardiac 
arrhythmias.   
 
EXPERIMENTAL PROCEDURES 
Materials  
Kv1.5-GFP and Kv1.5-mCherry constructs were generated from human Kv1.5 as 
previously described 
111
. Polyclonal anti-GFP, monoclonal anti-V5, and Alexa Fluor 
secondary antibodies were from Invitrogen (Carlsbad, CA). Polyclonal Anti-DsRed 
antibody was obtained from BD Biosciences Clontech (Palo Alto, CA). Anti-troponin I 
was obtained from Millipore (Billerica, MA).  Horseradish peroxidase-conjugated 
secondary antibodies were from Zymed (San Francisco, CA). HL-1 cells were a generous 
gift from Dr. William Claycomb (Louisiana State University Health Sciences Center, 
New Orleans, LA).  Dynasore was a generous gift from Dr. Tomas Kirchhausen 
(Department of Cell Biology, Harvard Medical School and the CBR Institute for 
Biomedical Research, Inc. Boston, Massachusetts).  Quinidine and quinine from Sigma 
(St. Louis, MO) were dissolved in DMSO and diluted 1:1000 into culture medium.  All 
vehicle was DMSO 1:1000 in culture medium equivalent to drug addition. 
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Western Blot  
HL1 cells were harvested in PBS containing Complete protease inhibitors (Roche 
Applied Science, Indianapolis, IN) and lysed in SDS-PAGE sample buffer. Proteins were 
then separated by SDS-PAGE on a NuPAGE‚ Novex 4-12% Bis-Tris gel (Invitrogen), 
transferred to nitrocellulose, and probed with the indicated primary antibody for 1 hr at 
4°C. Blots were then incubated with secondary antibodies conjugated to horseradish 
peroxidase (1:5000) and visualized using the Western Lightning enhanced 
chemiluminescent reagent according to the manufacturer’s protocol (Perkin- Elmer Life 
Sciences, Wellesley, MA). Images were captured using the EpiChemi3 Darkroom (UVP, 
Inc., Upland, CA). 
 
Immunocytochemistry 
For analyzing fluorescence data, background fluorescence was subtracted for each cell, 
prior to normalizing surface or internalized signal to the total GFP fluorescence of that 
cell. Normalized values for drug treated conditions were then expressed as percent of 
vehicle or, in some cases, normalized to maximal drug response. These values were 
calculated by the following equations. λ = wavelength at which the data were collected; 
λ1 = fluorophore 1, λ2 = fluorophore 2. 
For % Vehicle:   
                                                (Internalized[drug] λ1 – Background[drug] λ1) 
                                                      (GFP[drug] λ2 – Background[drug] λ2) 
                        100 ×              ________________________________ 
                           
                                             (Internalized[vehicle] λ1 – Background[vehicle] λ1) 
                                                    (GFP[vehicle] λ2 – Background[vehicle] λ2) 
36 
 
 
 
For % Max Internalization: 100 × 
 
 
      (Internalized[drug]λ1 - Background[drug]λ1)   _   (Internalized[vehicle]λ1 - Background[vehicle]λ1)  
        (GFP[drug] λ2 – Background[drug] λ2)                       (GFP[vehicle] λ2 – Background[vehicle] λ2) 
         ________________________________________________________________ 
 
  (Internalized[drug]max λ1 – Background[drug]max λ1) _ (Internalized[vehicle] λ1 – Background[vehicle]λ1) 
         (GFP[drug]max λ2 – Background[drug]max λ2)             (GFP[vehicle] λ2 – Background[vehicle] λ2) 
 
 
Immunocytochemistry was performed as previously described 
111
.  Briefly, 48 hr 
post transfection, HL-1 cells transiently expressing Kv1.5-GFP were live cell stained 
with a polyclonal anti-GFP antibody (1:500) in 2% goat serum for 30 min on ice to 
minimize internalization of membrane proteins.  For surface labeling, cells were then 
incubated with goat anti-rabbit Alexa Fluor secondary antibody (1:500) in 2% goat serum 
for 30 min on ice, fixed with 4% paraformaldehyde for 10 min on ice, and mounted with 
ProLong Gold anti-fade reagent (Invitrogen). For labeling surface and internalized 
protein following live-cell staining with anti-GFP, cells were treated with vehicle or drug 
for the specified amount of time prior to incubation with secondary antibody. Cells were 
then incubated with goat anti-rabbit Alexa Fluor 405 antibody (1:200) in 2% goat serum 
for 30 min on ice to saturate remaining surface channel populations, fixed with 4% 
paraformaldehyde for 10 min on ice, permeabilized with 0.1% Triton X-100 in 2% goat 
serum for 10 min on ice, incubated with goat anti-rabbit Alexa Fluor 647 antibody 
(1:500) in 2% goat serum for 30 min on ice, and mounted with ProLong Gold. Images of 
transfected cells displaying fluorescent signals were acquired on an Olympus Flouview 
500 confocal microscope with a 60 by 1.35 N.A. oil objective. Signal intensities were 
37 
 
adjusted so that the maximal pixel intensities were at least half saturation. Images were 
obtained by taking a series of images every 0.5 μm through the cell (generally 3–4 μm) 
and combining the images into a composite stack. To minimize effects of overexpression 
on Kv1.5-GFP localization, we analyzed only cells with low to mid levels of expressed 
protein.  Images were analyzed with ImageJ software (NIH, Bethesda, MD), and statistics 
were performed with Prism 5 software from GraphPad Prism Software (San Diego, CA).  
The resolution obtained in these imaging experiments was 512 by 512 pixels with a z 
resolution of 0.5μm for each filter set.  Regarding the laser configuration, Alexa Fluor 
405 was excited using a 405nm laser diode, reflected off of an SDM 490nm dichroic 
mirror, and passed through a BA 430-460nm bandpass filter.  Kv1.5-GFP was excited 
using a 488nm laser, reflected off of an SDM 560nm dichroic mirror, and passed through 
a BA505-525nm bandpass filter.  Alexa Fluor 594 was excited using a 543nm laser and 
passed through a BA560IF bandpass filter.  Alexa Fluor 647 was excited using a 633nm 
laser and passed through a BA660IF bandpass filter. Fluorescent signals of compressed 
Z-stacks were quantified using NIH ImageJ software (NIH, Bethesda, MD). To determine 
specific fluorescence, the background signal from neighboring untransfected cells was 
subtracted from the total fluorescence for all quantified signals. Surface and internalized 
Kv1.5 fluorescent signals were then normalized to total Kv1.5-GFP fluorescence for each 
cell. 
 
Recycling Assay:  The recycling assay was performed as previously described with the 
following modifications 
111
. 48 hr post-transfection, HL-1 cells transiently expressing 
Kv1.5-GFP were live-cell stained with an anti-GFP antibody (1:500) for 30 min on ice. 
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Following this incubation, the cells were returned to 37°C for 10 minutes with vehicle or 
drug, removed, and stained with goat anti-rabbit Alexa Fluor 594 secondary antibody 
(1:200) for 30 min on ice to saturate remaining surface channels. Cells were then returned 
to 37°C for the indicated times, removed, and incubated with goat-anti-rabbit Alexa Fluor 
405 (1:500) for 30 min on ice to detect the recycled channel population.   Additionally, 
cells were fixed and permeabilized as described above and internalized channel was 
detected with goat-anti-rabbit Alexa Fluor 647 (1:500) for 30 min on ice before mounting 
with ProLong Gold. 
 
Live-cell Imaging   
Kv1.5-pHluorin was generated by replacing the extracellular GFP tag with the pH 
sensitive variant of GFP, pHluorin. 48 hr post transfection HL-1 cells transiently 
expressing Kv1.5-pHluorin were imaged in a heated perfusion chamber using an 
Olympus FluoView 500 confocal microscope.  Both the chamber and perfusion solutions 
were maintained at 37°C throughout the experiment.  Cells were perfused with 
Liebovitz’s medium from Gibco (Carlsbad, CA) pH7.4 or Liebovitz’s medium containing 
0.1%DMSO for 10 minutes, followed by quinidine treatment for 10 minutes.  Images 
were collected using Olympus FluoView 500 (every 2.5 minutes at 1% laser intensity) 
and quantified as described above.    
 
Electrophysiology   
For electrophysiological studies, recordings were performed on HL-1 cells stably 
expressing Kv1.5-pHluorin and whole-cell voltage clamp experiments were performed as 
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described previously 
142
. The intracellular pipette solution contained (in mmol/L): 
Potassium aspartate 110, KCl
 
20, NaCl 8, HEPES 10, K2ATP 4, CaCl2 1, and MgCl2 1, 
either in the presence or absence of 10 mmol/L K2BAPTA; and was adjusted
 
to pH 7.2 
with KOH. The bath solution contained (in mmol/L):
 
NaCl 110, KCl 4, MgCl2 1, CaCl2 
1.8, HEPES 10, and glucose 1.8;
 
and was adjusted to pH 7.35 with NaOH.  All currents 
were normalized to the peak current measured at +60 mV for each cell tested.  All 
experiments were performed at room temperature. 
 
Neonatal Myocyte Isolation and Electroporation  
Cardiomyocytes from neonatal mice were isolated and cultured according to methods 
adapted
 
from Zlochiver, et al 
143
. Briefly, hearts from 1-3 day-old mice were
 
removed and 
collected in Ca
2+
- and Mg
2+
-free
 
Hank's balanced salt solution (HBSS) from Gibco. 
Finely minced cardiovascular tissue
 
was digested in 0.05% trypsin (Invitrogen) and 
0.001% pancreatin (Sigma) at 37°C
 
in consecutive 10 min steps. Supernatant cells 
suspensions were collected in an equal volume of medium M199 (Lonza BioWhittaker, 
Basel, Switzerland), containing 10% fetal bovine serum (FBS) from Gibco, 20 units/mL 
penicillin, 20 µg/mL streptomycin. Following 8 digestion steps, collected cell 
suspensions were centrifuged at 800 rpm for 5 min and the supernatant was aspirated and 
discarded.  The dissociated tissue was then resuspended in 10 mL medium and filtered 
through a 70 μm mesh filter into a 100mm tissue culture dish.  Fibroblasts were depleted 
through 2 hour preplating at 37˚C with 5% CO2.  Myocytes were collected off the dish by 
gentle agitation, filtered through a 40 μm mesh filter, and spun down for 1 min at 4,000 
rpm.  Myocytes were then resuspended in 100μL Nucleofector solution from Amaxa 
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(Gaithersburg, MD) and 2.5 μg of the desired DNA, per reaction.  This solution was then 
transferred to an Amaxa-certified cuvette, inserted into the cuvette holder of an Amaxa 
biosystems Nucleofector II, and program G-09 was run.  500μL of pre-warmed medium 
was then added to the solution in the cuvette and the myocytes were plated onto collagen-
coated coverslips in medium containing Bromodeoxyuridine (Sigma) and Fungizone 
(Gibco) and incubated in a humidified tissue culture incubator for 36-48 to allow protein 
expression.   
Statistical Analysis   
Statistics were performed using GraphPad Prism 5 Software (San Diego, CA).  All data 
are expressed as the mean ± SEM of n cells. Comparisons between
 
groups were made 
using a Student's t test (paired or unpaired) or One-way ANOVA as indicated. Values of
 
p<0.05 were considered significant.  
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Figure 2.1 Quinidine stimulates internalization of Kv1.5 in a dose- and temperature-
dependent manner. 
 
(A) Representative images of Kv1.5-GFP overexpressed in HL-1 cells, showing total 
GFP signal (left), surface channel as detected by surface labeling with anti-GFP followed 
by goat anti-rabbit Alexa Fluor 405 (middle), and internalized channel detected by 
labeling with goat anti-rabbit Alexa Fluor 647 (right), at 0min (top), 10min at 37°C with 
vehicle (0.1% DMSO) (middle), and 10min at 37°C with 100 μmol/L quinidine (bottom). 
(B) Quantification of internalized (top) and surface (bottom) Kv1.5 following treatment 
with increasing concentrations of quinidine for 10min at 37°C. (C) Comparison of dose 
response for Kv1.5-GFP internalization following quinidine treatment for 10min at room 
temperature (25˚C) and 37˚C (EC50 = 900 nmol/L at 37˚C).  Scale bars = 10 μm. * 
indicates p < 0.05; *** indicates p < 0.001 as determined by one-way ANOVA with 
Tukey post-test. 
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Figure 2.2 Quinidine treatment causes a reversible, dose-dependent open-channel 
block of Kv1.5. 
 
(A) Whole-cell voltage clamp experiments were performed on HL-1 cells stably 
expressing Kv1.5-pHluorin. Recordings were taken prior to and following 10 min 
perfusion with 1, 6, 10, or 100μmol/L quinidine and following 20 min of drug washout. 
Representative traces for sequential dosing of a single cell are shown. (B) Cells were 
treated as above and I-V curves were generated for cells prior to treatment and following 
10 min perfusion with 6, 10, and 100μmol/L quinidine. (C) I-V curves are shown for 
cells prior to treatment, and following 100μmol/L quinidine, and 20 min washout of 
quinidine. (D) A single depolarizing pulse to +60mV was applied as described in 
methods. Representative traces are shown for a single cell prior to and following 10, 12, 
and 15 min perfusion with 100 μmol/L quinidine. (E) Quantitation of internalized Kv1.5-
GFP (overexpressed in HL-1 cells) in response to 10 μmol/L quinidine for 5, 10, 15, 30, 
or 60 min at 37˚C. *** indicates p < 0.001 as determined by one-way ANOVA with 
Tukey post-test. 
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(A) Quantification of surface Kv1.5-pHluorin following perfusion at 37˚C for 10 min 
with 0.1% DMSO followed by 10 min with 100μmol/L quinidine and a brief pulse with 
50 mmol/L NH4Cl.  Representative images for each of these conditions are shown. (B) 
HL-1 cells expressing Kv1.5-pHluorin were perfused for 10 min with vehicle as 
described above. Remaining cell surface Kv1.5-pHluorin was photobleached at high laser 
intensity, followed by rapid application of NH4Cl, to reveal foci of intracellular, 
endosomal Kv1.5-pHluorin. Scale bar = 20μm. *** indicates p < 0.001 as determined by 
one-way ANOVA with Tukey post-test. 
 
 
 
Figure 2.3 Quinidine-induced internalization is independent of antibody labeling. 
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(A) Representative images of acutely dissociated neonatal mouse myocytes transiently 
expressing Kv1.5-GFP by electroporation showing total GFP signal (left), surface 
channel (left middle), internalized channel (right middle), and anti-troponin (right) signal, 
at 0min (top), 10min at 37°C with vehicle (middle), and 10min at 37°C with 100 μmol/L 
quinidine (bottom). Scale bars = 10 μm. (B) Quantification of internalized (left) and 
surface (right) Kv1.5 following treatment with 100 μmol/L quinidine for 10min at 37°C. 
*** indicates p < 0.001 as determined by unpaired t-test. 
 
 
 
 
Figure 2.4 Constitutive and quinidine-induced internalization occur in native mouse 
myocytes. 
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Dose-response for HL-1 cells expressing Kv4.2-GFP or Kv2.1-GFP (A) or Kv1.5-W472F 
(B) treated with increasing concentrations of quinidine for 10min at 37°C. ** indicates p 
< 0.01; *** indicates p < 0.001 as determined by one-way ANOVA with Tukey post-test. 
(C) Quantification of internalized Kv1.5 following treatment with 100 μmol/L quinidine 
or 200 μmol/L quinine, the diastereomer of quinidine, for 10min at 37°C. *** indicates p 
< 0.001 as determined by student’s unpaired t-test. 
 
Figure 2.5 Quinidine-induced internalization is subunit-dependent, activity- 
independent, and stereospecific. 
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HL-1 cells overexpressing Kv1.5-GFP or Kv4.2-GFP were (A) surface-labeled and the 
ratio of surface (red) to total protein (green) was quantified. Representative images are 
shown for both channel subunits. (B) Representative images of Kv1.5-GFP (top) or 
Kv4.2-GFP (bottom) showing total GFP signal (left), surface channel as detected by 
surface labeling with anti-GFP followed by goat anti-rabbit Alexa Fluor 405 (middle), 
and internalized channel detected by labeling with goat anti-rabbit Alexa Fluor 647 
(right), after 10min at 37°C with vehicle (0.1% DMSO). (C) Quantification of 
internalized Kv4.2 following treatment with increasing concentrations of quinidine for 
10min at 37°C.  Scale bar = 10μm. 
Figure 2.6 Surface to total protein ratio is similar for Kv1.5 and Kv4.2. 
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(A) Representative images showing total-GFP fluorescence patterns for Kv1.5 with an 
extracellular GFP tag, Kv2.1 with a C-terminal GFP tag, and Kv2.1 with an extracellular 
GFP tag. (B) HL-1 cells overexpressing Kv1.5-GFP or Kv2.1-GFP were surface-labeled 
and the ratio of surface (red) to total protein (green) was quantified. Representative 
images are shown for both channel subunits.  (C) Quantification of internalized Kv2.1 
following treatment with increasing concentrations of quinidine for 10min at 37°C.  Scale 
bar = 10μm.   
Figure 2.7 Kv2.1 differs from Kv1.5 in expression pattern; however, surface to total 
protein ratios are similar. 
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(A) Whole-cell voltage clamp experiments were performed on HL-1 cells stably 
expressing Kv1.5-pHluorin. Recordings were taken before and after 10 min perfusion 
with 20 or 100μmol/L quinine, and following 20 min of drug washout. Representative 
traces for sequential dosing of a single cell are shown. (B) Cells were treated as described 
above and I-V curves are shown for cells prior to treatment and following 10 min 
perfusion with 20 and 100μmol/L quinine. (C) I-V curves are shown for cells prior to 
treatment, and following 10 min perfusion with 100μmol/L quinine and 20 min washout 
of quinine.    
 
 
 
 
 
 
 
Figure 2.8 Quinine treatment causes a reversible, dose-dependent block of Kv1.5. 
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(A) Dose-response for HL-1 cells expressing Kv1.5-GFP or the quinidine-insensitive 
Kv1.5-T480A mutant treated with increasing concentrations of quinidine for 10min at 
37°C. (B)  Quinidine-induced internalization for HL-1 cells expressing Kv1.5-GFP 
containing the T480A, I508A, L510A, or V512A mutation treated with 100 μmol/L 
quinidine for 10min at 37°C. (C) Dose-Response for HL-1 cells expressing Kv1.5-GFP 
or the Kv1.5-P532L mutant treated as described in (A). * indicates p < 0.05; ** indicates 
p < 0.01; *** indicates p < 0.001 as determined by one-way ANOVA. 
 
 
 
 
Figure 2.9 Structural requirements for quinidine binding are partially conserved for 
pore block and channel internalization. 
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(A) HL-1 cells expressing Kv1.5-GFP were treated for 1 hour with 80 μmol/L Dynasore 
at 37˚C prior to surface-labeling with anti-GFP antibody. Quantification of internalized 
Kv1.5 following treatment with 100 μmol/L quinidine for 10min at 37°C in the continued 
presence of Dynasore. (B) Quantification of surface Kv1.5 for cells treated as described 
in (A). (C) Representative images of surface (red) and internalized (white) Kv1.5 in cells 
treated as described in (A). Scale bars = 10 μm. ** indicates p < 0.01; *** indicates p < 
0.001 as determined by one-way ANOVA with Tukey post-test. 
 
 
 
 
 
 
Figure 2.10 Channel internalization is prevented by pharmacologic disruption of the 
endocytic machinery. 
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(A) HL-1 cells co-expressing Kv1.5-mCherry and dynamitin-GFP were live-cell labeled 
with anti-DsRed followed by treatment with increasing concentrations of quinidine for 
10min at 37°C, and internalized Kv1.5 was quantified. (B) Quantification of surface 
Kv1.5 for cells treated as described in (A). * indicates p < 0.05; *** indicates p < 0.001 
as determined by one-way ANOVA with Tukey post-test. 
 
 
 
 
 
Figure 2.11 Channel internalization is prevented by dominant-negative disruption of 
the endocytic machinery. 
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Whole-cell voltage clamp experiments were performed on HL-1 cells stably expressing 
Kv1.5-pHluorin. A single depolarizing pulse to +60mV was applied as described in 
methods. (A) Current traces are shown for a single cell prior to (black) and following 
(gray) 10min exposure to 6 μmol/L quinidine in the presence (left) or absence (right) of 
BAPTA in the pipette solution (n=10 cells). (B) Dose-response curve upon treatment 
with increasing concentrations of quinidine for 10min at room temperature in the 
presence or absence of BAPTA in the pipette solution (IC50 = 13 μmol/L + BAPTA and 
3.5 μmol/L  - BAPTA; n=5 cells; Hill slope = 1.042 + BAPTA and 1.135 - BAPTA). (C) 
HL-1 cells expressing Kv1.5-GFP were pretreated for 1 hour with 10 μmol/L BAPTA-
AM before surface-labeling with anti-GFP antibody.  Quantification of internalized (left) 
and surface (right) Kv1.5 following treatment with 100 μmol/L quinidine for 10min at 
37°C in the continued presence of BAPTA-AM. Below each bar graph is a representative 
image for that condition.  Scale bars = 10 μm.  * indicates p < 0.05; ** indicates p < 0.01; 
*** indicates p < 0.001 as determined by one-way ANOVA with Tukey post-test. 
 
 
Figure 2.12 Quinidine-induced internalization occurs via a calcium-dependent 
mechanism. 
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Whole-cell voltage clamp experiments were performed on HL-1 cells stably expressing 
Kv1.5-pHluorin. I-V curves are shown for recordings taken in the presence (left) or 
absence (right) of BAPTA before and after 10 min perfusion with 6μmol/L quinidine.   
 
 
 
Figure 2.13 Quinidine-induced internalization occurs via a calcium-dependent 
mechanism. 
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Whole-cell voltage clamp experiments were performed on HL-1 cells stably expressing 
Kv1.5-pHluorin. (A) I-V curves for recordings taken prior to treatment and following 10 
min perfusion with 20μmol/L quinine in the presence or absence of BAPTA. (B) 
Quantification of Kv1.5 current following quinine treatment in the presence or absence of 
BAPTA. *** indicates p < 0.001 as determined by one-way ANOVA with Tukey post-
test.  
 
 
 
Figure 2.14 Quinine-mediated block of Kv1.5 current is calcium-independent. 
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(A) Quantification of recycled Kv1.5 at 0, 10, 20, 30, and 60 min at 37˚C post treatment 
with 100 μmol/L quinidine for 10 min at 37˚C.  Vehicle and quinidine treated data sets 
were each normalized to their own baseline (no washout) and maximum.  Corresponding 
total GFP levels are provided for 0 and 60 min of recycling (inset). Below are 
representative images showing the increase in recycled Kv1.5-GFP with time, post 
quinidine treatment. Scale bar = 10 μm. (B) HL-1 cells stably expressing Kv1.5-pHluorin 
were treated with 10 μmol/L quinidine for 0, 12, or 48 hours at 37°C. Quantification of 
total Kv1.5 protein levels normalized to actin and control (48 hour DMSO) levels. Below 
is a representative image of a Western blot for 0, 12, and 48 hours of quinidine treatment. 
(C) HL-1 cells stably expressing Kv1.5-pHluorin were treated with vehicle, 10 μmol/L 
quinidine, 10 μmol/L leupeptin, 500 nmol/L ALLN, quinidine and leupeptin, or quinidine 
and ALLN for 48 hours at 37°C (63%  or 67% decrease with 48 hr quinidine or quinidine 
and leupeptin (n = 8); no statistical decrease for quinidine and ALLN (n = 4)).  
Quantification was performed as in B. * indicates p < 0.05; ** indicates p < 0.01 as 
determined by one-way ANOVA with Tukey post-test.   
Figure 2.15 Acute quinidine-induced internalization is reversible, whereas chronic 
treatment results in channel degradation. 
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(A) Quantification of recycled Kv1.5 at 0, 10, 20, 30, and 60 min at 37˚C post treatment 
with 100 μmol/L quinidine for 10 min at 37˚C.  (B) HL-1 cells expressing Kv1.5-GFP 
were surface labeled with anti-GFP antibody, incubated 10 min in 100μmol/L quinidine 
at 37°C, and incubated 60 min in drug-free medium at 37°C, and surface Kv1.5 was 
quantified. (C) Quantification of surface Kv1.5, in HL-1 cells stably expressing Kv1.5, 
following treatment for 0, 12, 24, 36, or 48 hours at 37°C with 10μmol/L quinidine. *** 
indicates p < 0.001 as determined by one-way ANOVA with Tukey post-test. 
 
Figure 2.16 Recovery of surface Kv1.5 following acute, but not chronic, quinidine 
treatment. 
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CHAPTER 3  
 
A ROLE FOR MYOSIN V MOTOR PROTEINS IN THE SELECTIVE 
DELIVERY OF KV CHANNEL ISOFORMS TO THE MEMBRANE SURFACE 
OF CARDIAC MYOCYTES 
 
ABSTRACT 
Rationale: Kv1.5 (KCNA5) mediates the IKur current that controls atrial action potential 
duration. Given its atrial-specific expression and alterations in human atrial fibrillation 
(AF), Kv1.5 has emerged as a promising target for treatment of AF.  Contribution of 
drug-induced internalization to pore block of Kv1.5, highlights the importance of channel 
trafficking in drug development. A necessary step in the development of novel agents that 
selectively modulate trafficking pathways is identification of the cellular machinery 
controlling surface density, of which little is yet known.  
Objective: To investigate the role of the unconventional myosin V motors in determining 
the cell surface density of Kv1.5.   
Methods and Results: Western Blot analysis confirmed myosin Va and Vb expression in 
the heart, while disruption of endogenous motors selectively reduced IKur current in adult 
rat cardiomyocytes. Dominant negative (DN) myosin V constructs and shRNA silencing 
demonstrated a role for Va and Vb in the surface trafficking of Kv1.5, but not hERG 
(KCNH2).  Live-cell imaging of Kv1.5-GFP and retrospective labeling of actin tracts 
demonstrated motility of Kv1.5 vesicles.  Myosin Va participated in anterograde 
trafficking, while myosin Vb regulated post-endocytic recycling.  Over-expression of 
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mutant motors revealed a selective role for Rab 11 in coupling myosin Vb to Kv1.5 
recycling. 
Conclusions:  Myosin Va and Vb control functionally distinct steps in the surface 
trafficking of Kv1.5. These isoform-specific trafficking pathways determine the Kv1.5-
encoded IKur in adult myocytes to regulate repolarizing current and consequently cardiac 
excitability. Therapeutic strategies that manipulate specific trafficking pathways may 
prove useful in treatment of cardiovascular arrhythmias. 
 
INTRODUCTION 
The diversity and cell surface density of cardiovascular ion channels determines 
electrical profiles in the heart.  In the human atria, the voltage-gated potassium channel 
Kv1.5 underlies a major repolarizing current IKur.  The role of IKur in the control of action 
potential duration and atrial refractory period highlights its importance in atrial 
excitability and recognition as a major target for the treatment of AF. Despite the 
emergence of multiple compounds, some with promising atrial selectivity, effective 
cardioversion by IKur blockers as well as clinical efficacy and safety has yet to be 
achieved. Our recent demonstration of selective antiarrhythmic drug-induced 
internalization of Kv1.5 in atrial myocytes suggests a novel therapeutic avenue for acute 
termination of AF through alterations in ion channel trafficking.  One complication to this 
strategy is that during paroxysmal and persistent atrial fibrillation (AF), there is a marked 
reduction in IKur that is accompanied by a decrease in Kv1.5 protein expression.
144
 This 
contribution to electrical remodeling and evidence of decreased Kv1.5 sensitivity to 
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antiarrhythmic compounds during chronic AF
145
 highlights the need for understanding 
the molecular mechanisms regulating Kv1.5 surface density.   
Chronic AF is characterized by both electrical and structural remodeling that 
includes cytoskeletal rearrangement during the progression of this disease.
25, 146-148
 Given 
that protein trafficking is thought to occur through a cooperation of long-range trafficking 
along microtubules and short-range movement along actin filaments in the periphery, 
such a disruption could significantly abrogate cell surface levels and localization of 
cardiovascular ion channels. There is evidence for elements of the microtubule and actin 
cytoskeleton in the regulation of Kv1.5 current.
94, 101, 103, 107, 109-112, 142, 149, 150
 In general, 
however, the molecular machinery including the precise identities of the molecular 
motors and adaptors regulating ion channel trafficking in the cardiovascular system 
remain unknown.          
Cell surface density of ion channels is controlled by a balance of anterograde and 
retrograde trafficking. Previously, our lab has shown that Kv1.5 undergoes constitutive 
internalization and recycling at the atrial myocyte membrane.
111
  Internalization occurs 
through a dynamin-dependent, dynein-mediated microtubule pathway.
50, 111, 112
 
Internalized channel is then sorted into rab-dependent endocytic compartments, where 
association with Rab4- or Rab11-containing vesicles targets the channel for recycling 
back to the myocyte membrane, while association with Rab7-containing vesicles denotes 
degradation.
111-113
  An understanding of the mechanistic intricacies and how they differ 
for individual ion channels may reveal novel therapeutic targets for the regulation of 
channel densities and treatment of cardiovascular disease.  Here we report, for the first 
time, the role of unconventional myosin motors Va and Vb in determining the cell 
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surface level of Kv1.5 in cardiomyocytes, with myosin Vb coupling to Rab 11 for 
channel recycling.   
 
RESULTS 
Unconventional Myosin Motors Va and Vb Play a Functional Role in Determining 
IKur Current in Adult Rat Myocytes.    
Kv1.5 trafficking and cell surface density depends upon interaction with the actin 
cytoskeleton.  Disruption of the actin cytoskeleton with cytochalasin D has been shown to 
alter surface levels and current density of Kv1.5.
94, 103
  Moreover, Kv1.5 has been shown 
to directly interact via an N-terminal/core (T1) region with PDZ domains of PSD-95, 
SAP97, and alpha-actinin-2 in a manner critical for determining functional cell surface 
channel.
99, 101, 103, 107, 109
  While these data provide a link to the actin cytoskeleton, they do 
not address the potential trafficking of Kv1.5 along actin filaments for plasma membrane 
delivery.  Two candidate unconventional myosin motors, myosin Va and myosin Vb, 
transport cargo along actin filaments and have been shown to play a critical role in 
normal function and excitability in a number of cell types.
151
 While much has been 
discovered about the function of these motor proteins in the brain, little is known 
regarding their role in the excitability and function of cardiomyocytes.  Previous reports 
indicate that myosin Va and Vb mRNA is detected in the heart.
152, 153
  In order to 
demonstrate whether these myosin motor proteins were endogenously expressed in the 
cardiovascular system, we performed western blot analysis on lysates of rat heart, as well 
as HL-1 immortalized mouse atrial myocytes.  Compared to brain lysate controls, 
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labeling with isoform-specific antibodies demonstrated endogenous myosin Va and 
myosin Vb expression in both rat heart and HL-1 atrial myocytes (Figure 1A).   
To address the importance of myosin Va and myosin Vb in determining Kv1.5 
current levels in native myocytes, we developed adenoviral vectors coding for the cargo-
binding domain of myosin Va or Vb, which function as dominant-negative constructs by 
sequestering cargo in the presence of the endogenous motor.
154
 Infection of acutely 
dissociated adult rat ventricular myocytes with adenovirus was confirmed by 
visualization of fluorescence from RFP fused to both myosin V DN isoforms (Figure 1B).  
Isolation of the IKur current from adult myocytes was achieved by sequential whole cell 
voltage clamp traces using a -40 mV prepulse to inactivate Ito and a 10 min treatment 
with 50 µmol/L 4-Aminopyridine (4-AP) to selectively inhibit IKur (Figure 1C). The 
remaining Iss was then subtracted from the previous trace (IKur + Iss) to achieve a measure 
of IKur.  Infection with myosin Va DN or myosin Vb DN adenovirus resulted in a 
significant decrease in IKur current in acutely dissociated adult rat ventricular myocytes 24 
post infection, with a 53 ± 8% and 58 ± 6% decrease in IKur, respectively (n ≥ 7 
myocytes; p < 0.01 and 0.001, respectively) (Figure 1D).  Interestingly, myosin V DN 
infection did not alter corresponding Iss current in adult myocytes, demonstrating a lack 
of generalized toxicity due to adenoviral infection.  Myosin Va and Vb are endogenously 
expressed in the heart, and interference with myosin V-dependent trafficking results in a 
decrease in the Kv1.5-encoded IKur current in cardiomyocytes.   
 
Myosin Va and Vb Control Steady-state Cell Surface Levels of Kv1.5.   
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The selective decrease in IKur could be the result of alterations in channel conductance or 
in the cell surface density of Kv1.5 channel protein.  In order to investigate the 
underlying mechanism for the reduction in IKur, studies were initiated in HL-1 
immortalized mouse atrial myocytes expressing an extracellular GFP epitope-tagged 
Kv1.5 construct that mimics wild-type channel function.
50, 111
  In agreement with our 
native myocyte data, under whole cell voltage clamp, co-expression with myosin Va DN 
or myosin Vb DN resulted in a significant decrease in Kv1.5 current density (64 ± 29% 
and 34 ± 28% decrease in current density, respectively; n ≥ 5) (Figure 2A).  This decrease 
in current density was greater in the presence of both myosin V DN isoforms, resulting in 
a 92 ± 4% decrease in Kv1.5 current.  To determine whether the decrease in current 
density was the result of a decrease in cell surface trafficking, we measured the effect of 
co-expression of myosin Va DN or myosin Vb DN on steady-state cell surface levels of 
Kv1.5.  We found that co-expression of myosin Va DN or myosin Vb DN with Kv1.5 
resulted in a 47 ± 2% and 32 ± 3% decrease in surface channel, respectively (n ≥ 73, p < 
0.001) (Figure 2B, Supplemental Figure 1A).  Co-expression with both myosin V DN 
constructs further reduced cell surface Kv1.5 by 63 ± 2%.  In contrast, co-expression with 
either or both myosin V DN constructs did not alter the cell surface levels of extracellular 
tagged hERG-GFP (n ≥ 27) (Figure 2C, Supplemental Figure 1B).  This is consistent with 
the myocyte data demonstrating no effect of the myosin V DNs on Iss current, encoded by 
hERG and Kv2.1. The decrease in Kv1.5, not hERG, surface channel density indicates 
that myosin V motors may act selectively to traffic Kv channel isoforms.   
As an alternative, but complimentary approach for testing the role for myosin V 
motor proteins in the control of Kv1.5 surface density, we used a gene silencing 
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approach. We generated short hairpin RNA (shRNA) constructs targeted specifically 
against endogenous myosin Va and myosin Vb, which can avoid potential off-target 
effects with dominant-negative strategies.  To control for transfection efficiency the 
shRNA constructs were expressed using lentiviral vector infection.  The shRNA was 
shown to effectively downregulate the expression of recombinant myosin Va and Vb in 
transfected HL-1 myocytes (Supplemental Figure 2B, C).  shRNA knockdown resulted in 
a 53 ± 3% and 36 ± 9% decrease in myosin Va in response to shRNA Va 1 and Va 2, 
respectively (n = 3; p < 0.001 and 0.01, respectively) and a 54 ± 10% and 56 ± 9% 
decrease in myosin Vb in response to shRNA Vb 1 and Vb 2, respectively (n = 3, p < 
0.001) with no effect of scrambled shRNA virus.  As an additional control for shRNA 
specificity, HL-1 cells were transfected with myosin Va or myosin Vb carrying silent 
mutations (myosin V resistant) that create a partial mismatch with the shRNA sequence.  
Under these conditions, no decrease in corresponding myosin V motor protein expression 
was observed upon infection with myosin Va or Vb shRNA.   
With the effectiveness and specificity of the myosin gene silencing established, 
we measured the effects on Kv1.5 surface density.  Importantly, infection of cells 
expressing only Kv1.5-GFP resulted in a significant decrease in cell surface levels of 
channel in response to the myosin Va or Vb shRNA, but not the scrambled shRNA 
(Figure 2D, Supplemental Figure 2A).  This led to a 59 ± 2% and 51 ± 2% decrease after 
infection with myosin Va and Vb shRNA, respectively, with a significant difference 
between the two (n ≥ 93; p < 0.001).  Therefore, myosin Va- and myosin Vb-mediated 
trafficking plays a role in determining the steady-state cell surface levels and current 
density of Kv1.5. 
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Myosin Va and Vb Regulate the Intracellular Trafficking of Kv1.5 along Actin 
Filaments at the Periphery of the Myocyte. 
To investigate whether the decrease in Kv1.5 surface levels was due to a loss in channel 
trafficking on actin filaments, we first confirmed a role for the intact actin cytoskeleton in 
modulating surface density of the channel.  Acute treatment with cytochalasin D to 
inhibit actin polymerization resulted in a time-dependent decrease in surface Kv1.5 that 
was significant after one hour and culminated in a 56 ± 6% decrease after 6hr (n ≥ 85; p < 
0.001) (Figure 3A, Supplemental Figure 3).  To directly demonstrate the motility of 
Kv1.5 vesicles on actin filaments within myocytes, we performed live-cell, time-lapse 
imaging of Kv1.5-containing vesicles followed by retrospective immunofluorescence 
labeling and static imaging of the actin cytoskeleton (Figure 3B, Supplemental Movie 1). 
Kv1.5-GFP labeled vesicles were clearly visualized moving on phalloidin-labeled actin 
tracts at the myocytes periphery. Retrospective labeling of both phalloidin and tubulin 
showed Kv1.5-GFP vesicles moving in the anterograde direction on microtubules and 
transitioning to actin filaments at the myocyte edge (Supplemental Movie 2). To measure 
the ensemble characteristics of Kv1.5-GFP motility events, we used a standard deviation 
(SD) map to sum all motility events of a time series into one image.
149
  An overlay of the 
SD map of Kv1.5-GFP with a retrospectively labeled image of the actin cytoskeleton 
clearly demonstrates movement of Kv1.5-containing vesicles on linear tracts marked by 
phalloidin (Figure 3C).  This processivity of Kv1.5-containing vesicles on actin is lost in 
the presence of myosin Va DN or myosin Vb DN co-expression.  Quantification of 
trafficking events revealed that co-expression with either myosin V DN construct 
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significantly reduced both the average distance traveled and average net velocity of 
Kv1.5-contatining vesicles along actin filaments (Figure 3D).   
Kv1.5 alone exhibited an average travel distance of 0.8 µm and velocity of 
approximately 0.4 µm/s (400 nm/s) consistent with previous literature,
155-159
 whereas co-
expression with myosin Va DN and myosin Vb DN resulted in a 30 ± 1% and 33 ± 2% 
decrease in distance and velocity, respectively (n = 20 tracks from 16 cells, 17 tracks 
from 4 cells, and 9 tracks from 2 cells for Kv1.5 alone, Kv1.5 + myosin Va DN, and 
Kv1.5 + myosin Vb DN, respectively; p < 0.001).  Myosin Va and Vb contribute to the 
actin-based transport of Kv1.5 vesicles in HL-1 myocytes.   
 
Myosin V Isoforms Act at Distinct Steps in the Kv1.5 Trafficking Pathway. 
The additive nature of the myosin Va- and Vb-mediated decrease in current density and 
surface levels suggested that these two myosin V isoforms may function in different steps 
in the trafficking pathway of Kv1.5 (Figure 2B).  Myosin Va contributes to anterograde 
trafficking in a number of cell types,
160-162
 while myosin Vb is implicated in the post-
endocytic recycling of a number of proteins.
163-167
  Therefore, we next tested if this 
functional distinction of myosin Va and Vb in intracellular trafficking may be conserved 
in the cardiovascular system with Kv1.5.  Previously, we demonstrated acute inhibition 
of constitutive endocytosis of Kv1.5 with Dynasore, a small molecule inhibitor of 
dynamin.
50
  Disruption of dynamin-mediated endocytosis thereby permits investigation of 
the role of myosin Va and myosin Vb in the pre- and post-endocytic trafficking of Kv1.5.  
Introduction of a single point mutation S61D into the GTPase domain of dynamin 
significantly reduces the GTP hydrolysis efficiency resulting in a DN form of dynamin 
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for chronic inhibition of constitutive endocytosis.
168
  As with Dynasore, expression of 
dynamin S61D significantly increased steady-state cell surface Kv1.5 by 27 ± 5.3%, 
whereas overexpression of wild-type (WT) dynamin resulted in a 25 ± 2.6% decrease in 
surface Kv1.5 (n ≥ 110; p < 0.001) (Supplemental Figure 4A, B). More importantly, 
while co-expression with WT dynamin led to a significant increase, channel 
internalization was attenuated in the presence of dynamin S61D (Supplemental Figure 
4C, D).  Co-expression with WT dynamin resulted in a 30 ± 8.6% increase in internalized 
Kv1.5 versus a 39 ± 7.1% decrease in internalization in the presence of dynamin S61D (n 
≥ 69; p < 0.05, 0.001, and 0.01, respectively).  Based on these data we utilized co-
expression with the DN dynamin to elucidate whether myosin Va and Vb are acting 
upstream or downstream of channel endocytosis.  Dynamin S61D was able to block the 
myosin Vb DN-mediated decrease in steady-state cell surface Kv1.5 (Figure 4A, 
Supplemental Figure 5A, B).  In contrast, dynamin S61D was not able to alter the 
decrease in surface Kv1.5 mediated by myosin Va DN (n ≥ 59; p < 0.001).  These data 
suggest that myosin Va acts in the pre- and Vb in the post-endocytic trafficking of Kv1.5.  
The inability of dynamin S61D to induce an increase in steady-state surface Kv1.5 
(Supplemental Figure 4A) in the presence of myosin Vb DN may be the result of the 
incomplete block of constitutive endocytosis demonstrated in Supplemental Figure 4B.  
Myosin Vb DN may then inhibit the recycling of residual endocytosed channel.  To 
investigate the potential role of myosin Va in anterograde delivery of Kv1.5 to the plasma 
membrane we measured the effect of the myosin V DNs at 6hr of channel expression, a 
time point at which the majority of surface Kv1.5 is derived from anterograde delivery of 
newly synthesized channel.  At 6 hr of expression myosin Va DN, but not myosin Vb 
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DN, significantly reduced cell surface levels of Kv1.5 (41 ± 4.7%, n ≥ 25) (Figure 4B, 
Supplemental Figure 6A, B).  Myosin Va and Vb act in two distinct steps in the cell 
surface trafficking of Kv1.5, where myosin Va likely participates in anterograde 
trafficking to the plasma membrane, while myosin Vb acts in the post-endocytic 
trafficking of Kv1.5, likely through recycling of channel protein back to the plasma 
membrane.    
 
Myosin Vb-mediated Channel Recycling is Dependent Upon Coupling to Rab 11. 
Interaction of myosin Vb with recycling endosomes has been shown in the literature to 
occur through the adaptor protein Rab 11.
163-167, 169
 Previously, we have demonstrated a 
role of Rab 11, but not Rab 8, in the post-endocytic recycling of Kv1.5 in atrial 
myocytes.
111
  To test if myosin Vb is associating with Kv1.5-containing vesicles during 
channel recycling through the adaptor protein Rab 11, we utilized recently characterized 
mutations in myosin Vb that uncouple association with Rab-GTPases.
170
  Co-expression 
of Kv1.5 with the Rab 11 binding-deficient myosin Vb mutant Y1684E/Q1718R resulted 
in a 52 ± 1.5% decrease in channel surface density (n ≥ 74, p < 0.001) (Figure 5A, 
Supplemental Figure 7A).  In contrast, co-expression with the Rab 8 binding-deficient 
myosin Vb mutant Q1296L/Y1303C did not significantly alter the steady-state cell 
surface levels of Kv1.5.  We then utilized a live-cell recycling assay to observe the effect 
of the myosin V DN and Rab binding-deficient mutants on Kv1.5 channel recycling.  
Using this method, myosin Va DN and Rab 8 binding-deficient myosin Vb QL/YC did 
not significantly alter Kv1.5 channel recycling (Figure 5B, Supplemental Figure 7B).  In 
contrast, myosin Vb DN and Rab 11 binding-deficient myosin Vb YE/QR significantly 
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decreased channel recycling, resulting in a 72.5 ± 2.8% and 76 ± 2.2% decrease in 
recycled channel, respectively (n ≥ 60, p < 0.001).  To further demonstrate the necessity 
of Rab 11 coupling for myosin Vb-mediated recycling of Kv1.5, we co-expressed Kv1.5 
together with both the constitutively active (CA) Rab 11 construct and myosin Vb 
YE/QR.  As previously demonstrated, Rab 11 CA co-expression resulted in a significant 
increase in the steady-state cell surface levels of Kv1.5 (29 ± 3.5%, n ≥ 74, p < 0.001) 
(Figure 5C, Supplemental Figure 7C).  Interestingly, this increase in cell surface Kv1.5 
was abrogated by co-expression with myosin Vb YE/QR.  Furthermore, this loss of 
channel recycling through myosin Vb led to an accumulation of Kv1.5 in Rab 11 positive 
perinuclear endosomes in the presence of myosin Vb DN and Vb YE/QR, but not myosin 
Va or control (Figure 5D, Supplemental Figure 8).  Therefore, Kv1.5 channel recycling 
via myosin Vb occurs through selective Rab 11-mediated coupling to Kv1.5-contaning 
endosomes.  These coordinate trafficking events contribute to the steady-state cell surface 
levels of Kv1.5 channel protein and thereby likely play a role in determining the 
electrical excitability of native cardiac myocytes (Figure 6).  
 
DISCUSSION 
Here, we report a previously uncharacterized role of the myosin V motor family 
in the selective membrane trafficking of Kv1.5 in cardiac myocytes.  We elucidated the 
mechanism by which myosin Va and Vb act in functionally distinct steps in the cell 
surface trafficking of Kv1.5 to selectively determine IKur current density in adult 
myocytes. The subunit specificity and functional specialization demonstrated in this 
study denotes a potential therapeutic avenue for modulation of IKur in the treatment AF. 
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In considering channel trafficking pathways as valid therapeutic targets, it is 
important to consider that cell surface delivery of cardiovascular ion channels may occur 
through selective molecular trafficking mechanisms.  Unlike Kv1.5, myosin Va and Vb 
do not play a role in determining cell surface levels of hERG or Iss current.  This is 
somewhat surprising given that Loewen et al. demonstrated a common mechanism for K
+
 
channel retrograde microtubule-dependent trafficking by the dynein motor complex, 
including Kv2.1, Kv3.1, Kv4.3, hERG, and Kir2.1.
171
  In addition, we and others have 
demonstrated a role for the dynein motor complex in retrograde trafficking of Kv1.5.
111, 
112
  Potassium channel subunits also demonstrate a conserved mechanism for ER 
retention of misfolded protein through RXR motifs that are masked during proper protein 
folding.
76
  In contrast, there are distinct differences in the forward trafficking signals of 
channel subunits, implying a complex system for differential regulation of ER to Golgi 
trafficking.  In addition, different members of the MAGUK family have been shown to 
interact with specific K
+
 channel subunits to direct localization and regulate surface 
density.  In particular, overexpression of SAP97 has been shown to increase surface 
levels of Kv1.5
99, 107, 109
 and down-regulate other Kv channels
108
, while CASK 
participates in the targeting of Kir2 channels
172
.  Kv channel subunits also show a 
significant degree of specialization in their association with actin-binding proteins that 
effecting their stabilization or trafficking.  While alpha-actinin-2 directly interacts with 
Kv1.5,
94, 103, 110
 filamin interacts with Kv4.2
173
 and cortactin with Kv1.2
174
 to alter the cell 
surface levels of channel protein.  Therefore, while some mechanisms of K
+
 channel 
subunit trafficking may be conserved, there are also specialized steps along the 
trafficking pathway regulated by selective molecular motors, adaptors, and anchoring 
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proteins.  While additional channels would need to be investigated to determine the 
extent of selectivity of myosin Va and Vb for Kv1.5 channel trafficking, the data 
presented here further emphasize the potential for selectivity in ion channel trafficking 
pathways.   
Anterograde trafficking of Kv1.5 likely requires coordination of microtubule-
based trafficking with myosin Va-mediated transport. Recent evidence suggests that 
Kif5b mediates anterograde microtubule-based trafficking of Kv1.5.
150
  In addition, our 
laboratory has recently discovered a role for Kif17 in the post-Golgi transport and cell 
surface density of Kv1.5.
149
  It remains to be determined whether Kif5b and Kif17 
represent general or selective mechanisms for Kv channel trafficking.  Our live cell 
imaging data clearly shows the transfer from a microtubule to actin tracts at the cell 
periphery (Supplemental Movie 2).  Evidence of coordinated microtubule- and actin-
based trafficking components has sparked significant interest regarding the mechanism 
by which vesicles are transferred from one cytoskeletal network to the other.  One 
potential mechanism is that kinesin and myosin motors both reside on a single endosomal 
compartment,
175-177
 providing the opportunity to bind to and propagate along either 
cytoskeletal network in the vicinity of the endosome.  Another potential mechanism is the 
association of Rab GTPases with multiple motor proteins or subunits to link intracellular 
transport pathways.
169, 178
  For instance, Rab 4 interacts both with KIF3B and the light 
intermediate chain of dynein, while Rab 27a interacts with myosin Va and VIIa.
169
  In 
fact, the Rab GTPase-mediated coupling of distinct endosomal compartments to targeted 
transport processes has been well characterized.
169
  The importance of Rab 11 in myosin 
Vb-mediated membrane protein recycling has been demonstrated in diverse, non-
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cardiovascular systems.
163-167
  Rab 11 has also been implicated in non-anterograde 
delivery of Kv1.5 to the plasma membrane of rat atrial myocytes upon depletion of 
cholesterol, by an unknown molecular mechanism.
113
  Here, we demonstrate a direct 
coupling of myosin Vb to Rab 11 positive endosomes for the recycling of Kv1.5 in atrial 
myocytes.  None-the-less, the potential involvement of microtubule-based transport in 
channel recycling and possible role of Rab 11 in both trafficking components remains to 
be determined.  Recent large-scale profiling of Rab GTPase interactions highlights the 
unknown diversity of their binding partners for directing complex intracellular 
transport.
178
    Future studies are required to fully elucidate whether molecular motors, 
vesicular adaptors, or both exhibit selectivity for ion channel trafficking.  
While the modulation of trafficking pathways may have promise for acute 
cardioversion of arrhythmias, its role in the treatment of paroxysmal or persistent AF is 
less clear. AF is a progressive disorder marked by electrical and structural remodeling 
that becomes more established with prolonged arrhythmia.  Electrical remodeling is 
characterized by a significant decrease in atrial effective refractory period due to 
alterations in ion channel densities in the membrane.
25
  In addition, electrical remodeling 
of the atria has been demonstrated to alter sensitivity of ion channels to antiarrhythmic 
drug-mediated block.
145
  This may be due in part to the marked decrease in Kv channel 
surface density during AF,
25
 in particular Kv1.5 channel protein and IKur current,
144
 that 
would decrease the functional channel available for pore block by antiarrhythmic drugs. 
Therefore, the dependence of Kv1.5 trafficking on actin filaments demonstrated here may 
provide insight to explain the correlation between electrical and structural remodeling 
during AF. These two pathophysiologies may be mechanistically linked through the rate-
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induced induction of calcium-activated neutral proteases called calpains.
30, 31, 179
  
Calpains, activated by calcium overload during AF, mainly cleave cytoskeletal and 
membrane-associated proteins and may underlie the significant decrease in actin protein 
levels
180
 and disorganization of the cytoskeletal networks observed in AF.  Calpain has 
also been implicated in the degradation of alpha-actinin-2 during ischemia reperfusion 
injury.
181-184
  Kv1.5 directly interacts with alpha-actinin-2 through an N-terminal T1/core 
region and disruption of the actin cytoskeleton with cytochalasin or antisense 
oligonucleotide knockdown of alpha-actinin-2 alters channel current density.
94, 103, 110
  
Therefore, given the importance of the intact cytoskeleton and direct interaction with 
alpha-actinin-2 in determining the cell surface levels of Kv1.5 in myocytes, calpain 
activation may be a contributing mechanism that links cytoskeletal disruption to the 
decrease in IKur during AF.  In addition, our results predict that deterioration of the actin 
cytoskeleton would disrupt myosin-mediated delivery of Kv1.5 to the plasma membrane.  
Therefore, the ~ 50% decrease in IKur and Kv1.5 protein levels in AF may reflect a 
combination of decreased cell surface trafficking and enhanced endocytosis of Kv1.5 
leading to channel degradation.   
In summary, this report reveals the importance of the myosin V motors Va and 
Vb in regulating the plasma membrane targeting and cell surface density of Kv1.5 in the 
myocardium.  This is the first report of a role for these motor proteins in the trafficking 
and regulation of a cardiovascular ion channel with a functional consequence of their 
disruption.  As evidenced by these data, continued elucidation of the molecular 
machinery involved in cardiovascular ion channel trafficking may reveal novel 
73 
 
therapeutic targets for the regulation of channel densities and treatment of cardiovascular 
disease. 
 
EXPERIMENTAL PROCEDURES 
Materials  
Kv1.5-GFP was generated from human Kv1.5 as previously described.
111
 HL-1 cells 
were a generous gift from Dr. William Claycomb (Louisiana State University Health 
Sciences Center, New Orleans, LA). Polyclonal anti-GFP and Alexa Fluor secondary 
antibodies were from Invitrogen (Carlsbad, CA).  Horseradish peroxidase-conjugated 
secondary antibodies were from Zymed (San Francisco, CA).  Full-length mouse brain 
isoform myosin Va and rabbit polyclonal anti-myosin Va antibodies DiL2 123 and HAM-
5, and full-length mouse myosin Vb and rabbit polyclonal anti-myosin Vb antibodies 
were from Dr. John Hammer (NIH, Bethesda, MD) and Dr. Michael Ehlers (Duke 
University, Durham, NC), respectively.  Full-length myosin Va and Vb were tagged with 
3x-mCherry.  Myosin Va dominant-negative (DN)-RFP, myosin Vb DN-RFP, and Rab 
11 wild-type (WT) and constitutively active (CA) were provided by Dr. José Esteban 
(Universidad Autónoma de Madrid, Madrid, Spain).  Rab 11 WT was tagged with a c-
myc epitope tag.  Dynamin WT and S61D were a gift from Dr. Sandra Schmid (The 
Scripps Research Institute, La Jolla, CA).  Dynamin constructs were tagged with an HA 
epitope tag.  Full-length myosin Va and myosin Vb were tagged with 3x-mCherry and 
myosin Vb Y1684E/Q1718R and Q1296L/Y1303C were generated from full-length 
myosin Vb 3x-mCherry using the QuikChange® site-directed mutagenesis kit from 
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Stratagene (Santa Clara, CA).  Mouse anti-HA was purchased from Covance (Princeton, 
New Jersey).  Mouse anti-myc 9E10 was provided by Dr. Kristen Verhey.  Biotin-
conjugated goat anti-rabbit secondary antibody was purchased from Jackson 
ImmunoResearch Laboratories (West Grove, PA). Cy5-Streptavidin secondary antibody 
was purchased from GE Healthcare (Piscataway, NJ). Cytochalasin D from Sigma (St. 
Louis, MO) was dissolved in DMSO and diluted 1:1000 in culture medium.  All vehicle 
treatments were DMSO diluted 1:1000 in culture medium equivalent to drug addition.  
DNA transfection of HL-1 cells was carried out using Lipofectamine 2000 reagent 
(Invitrogen), according to the manufacturer's specifications. Lipofectamine 2000 was 
used at a ratio of 3:1 (3 μL Lipofectamine 2000 per 1 μg of DNA) in Opti-MEM I 
(Invitrogen). 0.5 μg of DNA was used for each construct transfected.  DsRed, more specifically 
pDsRed2-C1 from Clontech (Mountain View, CA), was used as a transfection control.   
 
Western Blot Analysis 
HL-1 cells were harvested by resuspension in lysis buffer (50 mmol/L tris/HCl, 150 
mmol/L NaCl, 5 mmol/L EDTA, 1% Triton) containing Complete protease inhibitors 
(Roche Applied Science, Indianapolis, IN).  40 µg of cell lysis sample was run on a 
NuPAGE, Novex 4-12% Bis-Tris acrylamide gel (Invitrogen). After electrophoretic 
transfer to nitrocellulose, membranes were incubated with primary anti-myosin Va, anti-
myosin Vb, or anti-tubulin (Sigma) antibodies (1:1000, 1:1000 or 1:2000 dilution 
respectively) for 1 hour at room temperature. Bound primary polyclonal antibody was 
detected with a 1:5000 dilution of HRP-conjugated goat anti-rabbit IgG (Invitrogen) for 
anti-myosin Va and anti-myosin Vb antibodies, or HRP-conjugated goat anti-mouse IgG 
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(Invitrogen) for anti-tubulin antibody and visualized using the Western Lightning 
enhanced chemiluminescent reagent according to the manufacturer’s protocol (Perkin- 
Elmer Life Sciences, Wellesley, MA).  Images were captured using the EpiChemi3 
Darkroom (UVP, Inc., Upland, CA). 
 
Adenovirus Preparation 
Myosin Va DN-RFP and myosin Vb DN-RFP were first cloned into the vector pENTR. 
Adenoviral constructs were generated using the vector pAD/V5/-dest (Invitrogen). 
Adenoviral constructs were digested with PacI and transfected into HEK293 cells. Crude 
viral lysates were produced from 10cm dishes and adenovirus was amplified by infection 
of HEK293 cells in 60 mm dishes. Virus was purified using the Virapur Adenovirus mini 
purification Virakit (Virapur, San Diego, CA) according to the manufacturer’s 
recommendations.  
 
Adult Rat Ventricular Myocyte Isolation 
The procedures used in this study were in accordance with the guidelines of the 
University of Michigan Committee on the Use and Care of Animals.  Veterinary care was 
provided by the University of Michigan Unit for Laboratory Animal Medicine.  The 
animal care and use program conformed to the standards in the Guide for the Care and 
Use of Laboratory Animals (NIH Publication No. 85-23, Revised 1996). Adult rat 
ventricular myocytes were isolated using previously established protocols.
185
  Briefly, 
Sprague-Dawley rats (~200g) were injected with 1500 U/Kg heparin. Following 
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dissection, each heart was mounted on a modified Langendorff apparatus and perfused 
for 2 min with oxygenated KHB-A (pH=7.4; in mmol/L:  NaCl 118; KCl 4.8; Hepes 25; 
K2HPO4 1.25; MgSO4 1.25; Glucose 11; CaCl2 1), followed by 5 min perfusion of 
oxygenated KHB-B (pH=7.4; in mmol/L:  NaCl 118; KCl 4.8; Hepes 25; K2HPO4 1.25; 
MgSO4 1.25; Glucose 11).  A recirculating enzyme solution (KHB-B perfusate 
containing ~0.5 mg/mL of collagenase type II and 0.017% blebbistatin), was applied for 
13 min. Isolated hearts were finely minced, gently run through a pipette, and cells were 
collected in sequential fractions. Cells were resuspended in KHB-A containing 2% BSA 
and 0.1% (v/v) blebbistatin, followed by resuspension in supplemented growth media 199 
containing 26 mmol/L NaHCO3,10 mmol/L L-glutathione, 0.2 g/L BSA, 5% FBS and 
1% P/S. Coverslips were precoated with Laminin and cells were plated at 2x10
4
 
cells/coverslip for 2 hours at 37°C. After the initial 1 hour, serum-free supplemented 
growth media was added to the cells with 20 µL of myosin Va DN or myosin Vb DN 
adenovirus (~0.7-1x10
12
 particles/mL) per 200 µL medium.  After 1 hour an additional 2 
mL of serum-free supplemented growth media was added.  Media was replaced 24 hr 
post-infection and electrophysiological recordings were taken.     
 
Electrophysiology 
For electrophysiological studies of HL-1 cells, recordings were performed on cells 
transiently expressing Kv1.5-GFP alone or co-expressing myosin Va DN-RFP, myosin 
Vb DN-RFP, or both DN isoforms.  Whole-cell voltage clamp experiments were 
performed as described previously.
142
 The intracellular pipette solution contained (in 
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mmol/L): Potassium aspartate 110, KCl
 
20, NaCl 8, HEPES 10, K2ATP 4, CaCl2 1, 
MgCl2 1, and K2BAPTA 10; and was adjusted
 
to pH 7.2 with KOH. The bath solution 
contained (in mmol/L):
 
NaCl 110, KCl 4, MgCl2 1, CaCl2 1.8, HEPES 10, and glucose 
1.8;
 
and was adjusted to pH 7.35 with NaOH. All currents were normalized to the peak 
current measured at +60 mV for each cell tested.  For electrophysiological studies of 
adult rat ventricular myocytes, current mediated by Kv1.5 (IKur) was determined using a 
series of 2 voltage protocols in conjunction with pharmacological inhibition of Kv1.5.  
Ca
2+
 current was inhibited by the addition of 200 µM CdCl to the bath solution.  Total 
current was obtained using a single 500 ms depolarizing pulse from -80 mV to +30 mV.  
The IKslow (IKur + Iss) current component was then isolated by the addition of a 100 ms 
pre-pulse to -40 mV to inhibit Na
+
 current and current mediated by Kv4.x channels (Ito), 
prior to depolarization to +30 mV.  The Iss (current mediated by Kv2.1 and hERG) 
current component was then isolated by perfusion with 50 µmol/L 4-AP prior to running 
the second voltage protocol.  IKur was obtained by electronic subtraction as the difference 
between IKslow and Iss.   
 
Immunocytochemistry 
Immunocytochemistry was performed and analyzed as previously described.
111
   
To measure steady-state surface Kv1.5 and hERG in the presence of myosin Va 
and Vb DN, HL-1 cells were transfected with either Kv1.5-GFP or hERG-GFP co-
transfected with DsRed, myosin Va DN-RFP, myosin Vb DN-RFP or both myosin Va 
and Vb DN-RFP.  48 hr post transfection, HL-1 cells were live cell stained with a 
polyclonal anti-GFP antibody (1:500) in 2% goat serum for 40 min on ice to minimize 
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internalization of membrane proteins.  For surface labeling, cells were then incubated 
with goat anti-rabbit Alexa Fluor 405 secondary antibody (1:500) in 2% goat serum for 
45 min on ice, fixed with 4% paraformaldehyde for 10 min on ice, and mounted with 
ProLong Gold anti-fade reagent (Invitrogen).  
To measure steady-state surface Kv1.5 in the presence of myosin Va and Vb 
shRNA, HL-1 cells were transfected with Kv1.5-GFP either alone, or co-infected with 
either scrambled, myosin Va, or myosin Vb shRNA lentivirus.  48 hr post transfection, 
HL-1 cells were live cell stained with a polyclonal anti-GFP antibody (1:500) in 2% goat 
serum for 40 min on ice to minimize internalization of membrane proteins.  For surface 
labeling, cells were then incubated with goat anti-rabbit Alexa Fluor 405 secondary 
antibody (1:500) in 2% goat serum for 45 min on ice, fixed with 4% paraformaldehyde 
for 10 min on ice, and mounted with ProLong Gold.  
To measure steady-state surface Kv1.5 in the presence of cytochalasin D, HL-1 
cells were transfected with Kv1.5-GFP.  48 hr post transfection, HL-1 cells were treated 
with DMSO for 30 min and 6 hr and with cytochalasin D for 30 min, 1 hr, 2 hr, 4 hr, or 6 
hr at 37°C.  HL-1 cells were then live cell stained with a polyclonal anti-GFP antibody 
(1:500) in 2% goat serum for 40 min on ice to minimize internalization of membrane 
proteins.  For surface labeling, cells were then incubated with goat anti-rabbit Alexa 
Fluor 405 secondary antibody (1:500) in 2% goat serum for 45 min on ice, fixed with 4% 
paraformaldehyde for 10 min on ice, and mounted with ProLong Gold. 
To measure steady-state surface Kv1.5 in the presence of dynamin WT or S61D, 
HL-1 cells were transfected with Kv1.5-GFP and co-transfected with DsRed, dynamin 
WT-HA, or dynamin S61D-HA.  48 hr post transfection, HL-1 cells were live cell stained 
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with a polyclonal anti-GFP antibody (1:500) in 2% goat serum for 40 min on ice to 
minimize internalization of membrane proteins.  For surface labeling, cells were then 
incubated with goat anti-rabbit Alexa Fluor 405 secondary antibody (1:500) in 2% goat 
serum for 45 min on ice.  Cells were then fixed with 4% paraformaldehyde for 10 min on 
ice, permeabilized with 0.1% Triton X-100 in 2% goat serum for 10 min on ice, and 
labeled for dynamin expression by incubation with mouse anti-HA (1:500) in 2% goat 
serum for 40 min on ice, followed by incubation with goat anti-mouse Alexa Fluor 594 
antibody (1:500) in 2% goat serum for 40 min on ice and mounted with ProLong Gold.  
To measure internalized Kv1.5 in the presence of dynamin WT or S61D, HL-1 
cells were transfected with Kv1.5-GFP and co-transfected with DsRed, dynamin WT-
HA, or dynamin S61D-HA.  48 hr post transfection, HL-1 cells were live cell stained 
with a polyclonal anti-GFP antibody (1:500) in 2% goat serum for 40 min on ice to 
minimize internalization of membrane proteins.  Cells were then incubated at 37°C for 0 
or 30 min to allow for internalization of channel with primary antibody prior to 
incubation with goat anti-rabbit Alexa Fluor 405 antibody (1:200) in 2% goat serum for 
45 min on ice to saturate remaining surface channel populations.  Cells were then fixed 
with 4% paraformaldehyde for 10 min on ice, permeabilized with 0.1% Triton X-100 in 
2% goat serum for 10 min on ice, and internalized channel was labeled by incubation 
with goat anti-rabbit Alexa Fluor 647 antibody (1:500) in 2% goat serum for 35 min on 
ice.  Dynamin expression was then labeled by incubation with mouse anti-HA (1:500) in 
2% goat serum for 40 min on ice, followed by incubation with goat anti-mouse Alexa 
Fluor 594 antibody (1:500) in 2% goat serum for 40 min on ice and mounted with 
ProLong Gold. 
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To measure steady-state surface Kv1.5 in the presence of myosin Va or Vb DN 
and dynamin S61D, HL-1 cells were transfected with Kv1.5-GFP and co-transfected with 
DsRed, myosin Va DN-RFP, myosin Va DN-RFP + dynamin S61D-HA, myosin Vb DN-
RFP, or myosin Vb DN-RFP + dynamin S61D-HA.  48 hr post transfection, HL-1 cells 
were live cell stained with a polyclonal anti-GFP antibody (1:500) in 2% goat serum for 
40 min on ice to minimize internalization of membrane proteins.  For surface labeling, 
cells were then incubated with goat anti-rabbit Alexa Fluor 405 secondary antibody 
(1:500) in 2% goat serum for 45 min on ice.  Cells were then fixed with 4% 
paraformaldehyde for 10 min on ice, permeabilized with 0.1% Triton X-100 in 2% goat 
serum for 10 min on ice, and labeled for dynamin expression by incubation with mouse 
anti-HA (1:500) in 2% goat serum for 40 min on ice, followed by incubation with goat 
anti-mouse Alexa Fluor 647 antibody (1:500) in 2% goat serum for 40 min on ice and 
mounted with ProLong Gold. 
To measure newly-synthesized surface Kv1.5 in the presence of myosin Va or Vb 
DN, HL-1 cells were transfected with Kv1.5-GFP and co-transfected with DsRed, myosin 
Va DN-RFP or myosin Vb DN-RFP.  At 6 hr of expression (post the 4 hr incubation in 
serum-free medium for transfection) HL-1 cells were live cell stained with a polyclonal 
anti-GFP antibody (1:500) in 2% goat serum for 40 min on ice to minimize 
internalization of membrane proteins.  For surface labeling, cells were then incubated 
with goat anti-rabbit Alexa Fluor 405 secondary antibody (1:500) in 2% goat serum for 
45 min on ice, fixed with 4% paraformaldehyde for 10 min on ice, and mounted with 
ProLong Gold.  
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To measure steady-state surface Kv1.5 in the presence of the myosin Vb mutants, 
HL-1 cells were transfected with Kv1.5-GFP and co-transfected with DsRed, myosin Vb 
mutant Y1684E/Q1718R-mCherry (Rab 11 binding-deficient), or myosin Vb mutant 
Q1296L/Y1303C-mCherry (Rab 8 binding-deficient). 48 hr post transfection, HL-1 cells 
were live cell stained with a polyclonal anti-GFP antibody (1:500) in 2% goat serum for 
40 min on ice to minimize internalization of membrane proteins.  For surface labeling, 
cells were then incubated with goat anti-rabbit Alexa Fluor 405 secondary antibody 
(1:500) in 2% goat serum for 45 min on ice, fixed with 4% paraformaldehyde for 10 min 
on ice, and mounted with ProLong Gold. 
To measure recycled Kv1.5 in the presence of the myosin DNs and myosin Vb 
mutants, HL-1 cells were transfected with Kv1.5-GFP and co-transfected with DsRed, 
myosin Va DN-RFP, myosin Vb DN-RFP, myosin Vb mutant Y1684E/Q1718R-mCherry 
(Rab 11 binding-deficient), or myosin Vb mutant Q1296L/Y1303C-mCherry (Rab 8 
binding-deficient).  48 hr post transfection, HL-1 cells were live cell stained with a 
polyclonal anti-GFP antibody (1:500) in 2% goat serum for 40 min on ice to minimize 
internalization of membrane proteins.  Cells were then incubated at 37°C for 30 min to 
allow for internalization of channel with primary antibody.  Cells were then incubated 
with goat anti-rabbit Alexa Fluor 405 antibody (1:200) in 2% goat serum for 45 min on 
ice to saturate remaining surface channel populations.  Cells were then returned to 37°C 
for 60 min, removed, and incubated with goat anti-rabbit biotinylated antibody (1:500) in 
2% goat serum for 40 min on ice.  Cells were then incubated with streptavidin-Cy5 
(1:500) in 2% goat serum for 40 min on ice, and mounted with ProLong Gold.  
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To measure steady-state surface Kv1.5 in the presence of Rab 11 CA and Rab 11 
binding-deficient myosin Vb, HL-1 cells were transfected with Kv1.5-GFP and co-
transfected with DsRed, Rab 11 CA-RFP, myosin Vb mutant Y1684E/Q1718R-mCherry 
(Rab 11 binding-deficient), or Rab 11 CA-RFP and myosin Vb mutant Y1684E/Q1718R-
mCherry.  48 hr post transfection, HL-1 cells were live cell stained with a polyclonal 
anti-GFP antibody (1:500) in 2% goat serum for 40 min on ice to minimize 
internalization of membrane proteins.  For surface labeling, cells were then incubated 
with goat anti-rabbit Alexa Fluor 405 secondary antibody (1:500) in 2% goat serum for 
45 min on ice, fixed with 4% paraformaldehyde for 10 min on ice, and mounted with 
ProLong Gold. 
To observe co-localization of Kv1.5 with Rab 11 positive endosomes, HL-1 cells 
were transfected with Kv1.5-GFP and co-transfected with Rab 11-myc and with DsRed, 
myosin Va DN-RFP, myosin Vb DN-RFP, or myosin Vb mutant Y1684E/Q1718R-
mCherry (Rab 11 binding-deficient).  48 hr post transfection, HL-1 cells were live cell 
stained with a polyclonal anti-GFP antibody (1:500) in 2% goat serum for 40 min on ice 
to minimize internalization of membrane proteins.  Cells were then incubated at 37°C for 
30 min to allow for internalization of channel with primary antibody.  Cells were then 
incubated with goat anti-rabbit Alexa Fluor 405 antibody (1:200) in 2% goat serum for 45 
min on ice to saturate remaining surface channel populations.  Cells were then returned to 
37°C for 60 min, removed, fixed with 4% paraformaldehyde for 10 min on ice, 
permeabilized with 0.1% Triton X-100 in 2% goat serum for 10 min on ice, and labeled 
for Rab 11 expression by incubation with mouse anti-myc (1:500) in 2% goat serum for 
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40 min on ice, followed by incubation with goat anti-mouse Alexa Fluor 647 antibody 
(1:500) in 2% goat serum for 40 min on ice and mounted with ProLong Gold. 
Images of transfected cells displaying fluorescent signals were acquired on an 
Olympus Flouview 500 confocal microscope with a 60 by 1.35 N.A. oil objective or a 
Nikon TI81 A1R confocal microscope with a 60 by 1.40 N.A. oil objective. Signal 
intensities were adjusted so that the maximal pixel intensities were at least half saturation. 
Images were obtained by taking a series of images every 0.5 μm through the cell 
(generally 3–4 μm) and combining the images into a composite Z-stack. To minimize 
effects of overexpression on Kv1.5-GFP localization, we analyzed only cells with low to 
mid levels of expressed protein.  Each immunocytochemical experiment was performed a 
minimum of three times.  While the microscope settings were optimized for each 
experimental group, they were kept consistent for every repetition of a given experiment. 
For every repetition of a given experiment, 10-20 images were acquired for each 
condition.  Overall, approximately 30-100 cells were analyzed for each condition of an 
experimental group.  Fluorescent signals of Z-stacks were quantified with ImageJ 
software (NIH, Bethesda, MD) by drawing a region of interest around each analyzable 
cell and a neighboring untransfected cell in the image and measuring the average 
fluorescence intensity for each fluorescent signal for every region of interest.  To 
determine specific fluorescence, the average fluorescence intensity measured for each 
fluorescent signal from a neighboring untransfected cell was subtracted from the 
corresponding fluorescent signal measured for each transfected cell. The ratio of surface, 
internalized, or recycled Kv1.5 fluorescent signals to total Kv1.5-GFP fluorescence was 
then calculated for each cell.  Normalized surface, internalized, and recycled Kv1.5 
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values were then expressed as percent change from the control condition.  Statistical 
analysis was performed using Prism 5 software from GraphPad Prism Software (San 
Diego, CA).  The resolution obtained in these imaging experiments was 512 by 512 
pixels with a z resolution of 0.5μm for each filter set.   
 
Design of shRNA and shRNA Resistant Constructs of Myosin Va and Vb  
Four shRNA sequences targeting myosin Va and Vb were designed using shRNA 
sequence designer (Invitrogen). Sequences used to target myosin Va were as follows: 5’-
GCAAAGCACATCTATGCAAAG (nucleotides 1210-2130 – Va 1) and 5’-
GATCATTGCTGAC ATCAAC (nucleotides 4632-4650 – Va 2). Sequences used to 
target myosin Vb were as follows: 5’-GGACCTACCTGACTTCTTCA (nucleotides 
2096-2116 – Vb 1) and 5’-GCTGAAGGC CCTCAAGATTGA (nucleotides 2709-2729 – 
Vb 2). The scrambled shRNA sequence had the same nucleotide composition as shRNA 
targeting myosin Vb (nucleotides 2709-2729) but with randomized order creating 
mismatch with any mRNA sequence in the mouse nucleotide database: 5-
GCAAGCGATACGGCGACTTTA (siRNA Wizard). For shRNA resistant myosin 
constructs, the QuikChange® site-directed mutagenesis kit (Stratagene) was used to make 
silent mutations in wild-type myosin Va (C1218T, C1221T and T1224C) and wild-type 
myosin Vb (C2718A, C2719T, C2721A and G2724A) to create partial mismatch between 
the shRNA sequence and targeted mRNA.  
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Lentiviral Vector Construction, Virus Production, and Infection 
Plasmids containing myosin Va, myosin Vb or scrambled shRNA were constructed by 
Lenlox3.7 in order to obtain lentivirus. Five pairs of complementary DNA oligo 
nucleotides containing shRNA sequences were synthesized by IDT (Integrated DNA 
technologies) and hybridized to generate dsDNA. Each dsDNA was cloned into a lenlox 
3.7 vector and the recombinant lentiviral vectors were produced by transfection into 
human HEK293T cells. 48 hours post transfection, viral supernatants were collected and 
filtered through a 0.45 um filter. To find a minimum effective multiplicity of infection 
(MOI), several MOI doses (1, 5, 10, 20 µl) of lentiviral preparations were used to infect 
HL-1 cells. The minimum effective dose was estimated by qRTPCR after 48 hours of 
infection (data not shown).  Following transfection, growth media was added to the HL-1 
cells with 20 µL of scrambled, myosin Va, or myosin Vb shRNA lentivirus per 2 mL 
medium.   
 
Live-cell Imaging 
HL-1 cells in glass-bottom dishes (MatTek) were imaged live on a Nikon TE2000 
microscope with a Plan-APO 100X/NA1.4 objective and Photometrics CS ES2 camera.  
16-20 hours post transfection HL-1 cells transiently expressing Kv1.5-GFP alone or in 
the presence of myosin Va or myosin Vb DN were imaged every 3 seconds for 30 
minutes.  Both the objective and perfusion solutions were maintained at 37°C throughout 
the experiment.  Cells were maintained in phenol free DMEM for the duration of 
imaging.  Immediately after imaging cells were fixed for 7 min with 4% 
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paraformaldehyde, quenched for 10 min with 50 mmol/L NH4Cl, permeabilized for 10 
min in 0.1% Triton X-100 in 2% goat serum in PBS, and washed 2 times for 5 min with 
PBS and once for 10 min in PBS with rhodamine conjugated phalloidin (1:1000) to label 
actin filaments.  Images were prepared with ImageJ (NIH) and Photoshop CS2 (Adobe).  
Generation of the SD maps and speed and run length of vesicles using home-made plug-
ins for ImageJ were performed as described previously.
149
  For colocalization of Kv1.5-
GFP with actin filaments, the SD map of vesicle motility was overlaid with a static image 
of the rhodamine-phalloidin fluorescence.  
 
Statistical Analysis  
Statistics were performed using GraphPad Prism 5 Software (San Diego, CA).  All data 
are expressed as the mean ± SEM of n cells. Comparisons between
 
groups were made 
using One-way ANOVA as indicated. Values of
 
p<0.05 were considered significant.  
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Figure 3.1 Endogenous myosin Va and myosin Vb regulate IKur. 
 
(A) Representative western blot image of endogenous myosin Va and Vb and tubulin 
from non-transfected HL1 cells and rat heart and brain. (B) Representative images of 
adult rat ventricular myocytes demonstrating RFP fluorescence and differential 
interference contrast (DIC) for a non-infected myocyte and myocytes 24 hr post infection 
with myosin Va or Vb DN adenovirus. (C) Representative traces depicting the voltage 
protocol, pharmacological steps, and electronic subtraction for isolation of IKur current in 
acutely dissociated rat ventricular myocytes. (D) Quantification of IKur and Iss current, and 
representative traces of IKur current, in acutely dissociated adult rat ventricular myocytes 
24 hr post infection with myosin Va DN or myosin Vb DN adenovirus (n ≥ 7 myocytes). 
* indicates p < 0.05; ** indicates p < 0.01 as determined by one-way ANOVA with 
Tukey post-test.   
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Figure 3.2 Disruption of myosin Va and Vb function decreases current density and 
cell surface levels of Kv1.5. 
 
HL-1 cells transiently expressing Kv1.5-GFP or hERG-GFP co-expressing DsRed vector 
control, or myosin Va DN or myosin Vb DN alone or in combination 48 hr post 
transfection. (A) Representative whole cell voltage clamp current traces and the 
corresponding IV curve for Kv1.5 current density (n ≥ 5 cells). (B) Quantification of 
surface Kv1.5 with representative images for each condition (n ≥ 73 cells). (C) 
Quantification of surface hERG with representative images for each condition (n ≥ 27 
cells). (D) Quantification of surface Kv1.5 in HL-1 cells transiently expressing Kv1.5-
GFP following 48 hr of lentiviral infection with scrambled, myosin Va, or myosin Vb 
shRNA (n ≥ 93 cells).  Below are representative images for each condition. Scale bars = 
10µm. * indicates p < 0.05; *** indicates p < 0.001 as determined by one-way ANOVA 
with Tukey post-test.   
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Figure 3.3 Co-expression with myosin Va or Vb DN does not alter total channel. 
 
Quantification of total GFP in HL-1 cells transiently expressing either (A) Kv1.5-GFP or 
(B) hERG-GFP and co-expressing DsRed vector control or myosin Va DN or myosin Vb 
DN alone or in combination 48 hr post transfection (n ≥ 73 and n ≥ 27 cells, 
respectively). 
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(A) Quantification of total GFP in HL-1 cells transiently expressing Kv1.5-GFP 48 hr 
post transfection and lentiviral infection with scrambled, myosin Va, or myosin Vb 
shRNA (n ≥ 93 cells).  HL-1 cells transiently expressing full-length wild-type (left) and 
shRNA resistant (right) myosin Va (B) or myosin Vb (C) 48 hr post transfection and 
infection with lentiviral shRNA. Quantification of total myosin Va and myosin Vb 
normalized to tubulin loading control in response to two targeted lentiviral constructs 
compared to non-infected, scrambled shRNA, and shRNA resistant controls (n = 3 blots). 
Below are representative images of corresponding western blots. * indicates p < 0.05; ** 
indicates p < 0.01; *** indicates p < 0.001 as determined by one-way ANOVA with 
Tukey post-test.   
Figure 3.4 Lentiviral shRNA targeting myosin Va and Vb does not alter total Kv1.5-
GFP and specifically knocks down the respective myosin isoform. 
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Figure 3.5 Processivity of Kv1.5-containing vesicles is lost upon inhibition of myosin 
Va and Vb function. 
 
(A) Quantification of surface channel and representative images for HL-1 cells 48 hr post 
transfection with Kv1.5-GFP. Cells were treated with 0.1% DMSO vehicle control or 5 
µmol/L cytochalasin D for 0.5, 1, 2, 4, and 6 hr (n ≥ 85 cells). Live cell imaging of HL-1 
cells transiently expressing Kv1.5-GFP alone or co-expressing myosin Va DN or myosin 
Vb DN 16-20 hr post transfection, followed by retrospective labeling for actin filaments 
with rhodamine-phalloidin. (B) A cartoon representation and representative image of the 
protocol for live cell imaging of Kv1.5-contatining vesicle trafficking and retrospective 
actin filament labeling. (C) Representative images showing the SD map for Kv1.5-
containing vesicle motility, rhodamine phalloidin fluorescence, and the merged image. 
(D) Quantification of the distance traveled and velocity of Kv1.5-containing vesicles 
trafficking along actin filaments in the periphery of the cell (n = 20 tracks from 16 cells, 
17 tracks from 4 cells, and 9 tracks from 2 cells for Kv1.5 alone, Kv1.5 + myosin Va DN, 
and Kv1.5 + myosin Vb DN, respectively). Scale bars = 10µm. * indicates p < 0.05; ** 
indicates p < 0.01; *** indicates p < 0.001 as determined by one-way ANOVA with 
Tukey post-test.   
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Figure 3.6 Treatment with cytochalasin D does not alter total Kv1.5-GFP. 
 
Quantification of total GFP in HL-1 cells 48 hr post transfection with Kv1.5-GFP.  Cells 
were treated with 0.1% DMSO vehicle control or 5 µmol/L cytochalasin D for 0.5, 1, 2, 
4, and 6 hr (n ≥ 85 cells). 
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Figure 3.7 Myosin Va acts in the anterograde and myosin Vb in the post-endocytic 
trafficking of Kv1.5. 
 
HL-1 cells transiently expressing Kv1.5-GFP 48 hr post transfection. (A) Quantification 
and representative images of steady-state surface Kv1.5 upon co-expression with DsRed, 
myosin Va DN, myosin Va DN + dynamin S61D, myosin Vb DN, or myosin Vb DN + 
dynamin S61D (n ≥ 59 cells). (B) Quantification and representative images of newly 
synthesized surface Kv1.5 6 hr post expression of Kv1.5-GFP co-transfected with DsRed, 
myosin Va DN or myosin Vb DN (n ≥ 25 cells). Scale bars = 10µm. * indicates p < 0.05; 
*** indicates p < 0.001 as determined by one-way ANOVA with Tukey post-test.   
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Figure 3.8 Co-expression with dynamin WT or S61D does not alter total Kv1.5-GFP. 
 
HL-1 cells transiently expressing Kv1.5-GFP and co-expressing DsRed, WT dynamin, or 
dynamin S61D 48 hr post transfection. (A) Quantification and representative images of 
steady-state surface Kv1.5 (n ≥ 110 cells). (B) Quantification of total GFP when 
measuring steady-state surface Kv1.5.  (C) Quantification and representative images of 
internalized Kv1.5 (n ≥ 69 cells). (D) Quantification of total GFP when measuring 
internalized Kv1.5. Scale bars = 10µm. * indicates p < 0.05; ** indicates p < 0.01; *** 
indicates p < 0.001 as determined by one-way ANOVA with Tukey post-test.   
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HL-1 cells transiently expressing Kv1.5-GFP and co-expressing DsRed, myosin Va DN, 
myosin Va DN + dynamin S61D, myosin Vb DN, or myosin Vb DN + dynamin S61D. 
(A) Quantification of total GFP (n ≥ 59 cells). (B) Representative images of anti-GFP 
labeling for surface channel (left, white), total Kv1.5-GFP (left middle, green), DsRed or 
myosin V DN-RFP fluorescence (right middle, red), and anti-HA labeling for dynamin 
S61D (right, magenta).  
Figure 3.9 Co-expression with myosin Va or Vb DN and dynamin S61D does not 
alter total Kv1.5-GFP. 
96 
 
 
 
 
 
Quantification of (A) total GFP and (B) total DsRed/RFP in HL-1 cells 6 hr post 
expression of Kv1.5-GFP co-expressing DsRed, myosin Va DN or myosin Vb DN (n ≥ 
25 cells).  
 
Figure 3.10 Co-expression with myosin Va or Vb DN at an early time point does not 
alter total Kv1.5-GFP. 
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Figure 3.11 Recycling of Kv1.5 requires selective interaction of myosin Vb with Rab 
11. 
 
Quantification and representative images of HL-1 cells transiently expressing Kv1.5-GFP 
48 hr post transfection. (A) Steady-state surface Kv1.5 upon co-expression with DsRed, 
myosin Vb YE/QR, or myosin Vb QL/YC (n ≥ 74 cells). (B) Recycled Kv1.5 upon co-
expression with DsRed, myosin Va DN, myosin Vb DN, myosin Vb YE/QR, or myosin 
Vb QL/YC (n ≥ 60 cells). (C) Steady-state surface Kv1.5 upon co-expression with Rab 
11 CA, myosin Vb YE/QR, or Rab 11 CA and myosin Vb YE/QR (n ≥ 74 cells). (D) Co-
localization for Kv1.5-GFP, Rab 11, and myosin Va DN, myosin Vb DN, or myosin Vb 
YE/QR in perinuclear endosomes. Scale bars = 10µm. *** indicates p < 0.001 as 
determined by one-way ANOVA with Tukey post-test.   
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(A) Quantification of total GFP in HL-1 cells transiently expressing Kv1.5-GFP and co-
expressing DsRed, myosin Vb YE/QR, or myosin Vb QL/YC 48 hr post transfection (n ≥ 
74 cells). (B) Quantification of total GFP in HL-1 cells transiently expressing Kv1.5-GFP 
and co-expressing DsRed, myosin Va DN, myosin Vb DN, myosin Vb YE/QR, or 
myosin Vb QL/YC 48 hr post transfection (n ≥ 60 cells). (C) Quantification of total GFP 
in HL-1 cells transiently expressing Kv1.5-GFP and co-expressing Rab 11 CA, myosin 
Vb YE/QR, or Rab 11 CA and myosin Vb YE/QR 48 hr post transfection (n ≥ 74 cells). 
Figure 3.12 Co-expression with myosin Vb mutants or myosin V DNs does not alter 
total Kv1.5-GFP. 
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HL-1 cells transiently expressing Kv1.5-GFP and Rab 11 WT, and co-expressing myosin 
Va DN, myosin Vb DN, or myosin Vb YE/QR 48 hr post transfection. Representative 
images of total Kv1.5-GFP (left, green), DsRed or myosin V DN-RFP or myosin Vb 
YE/QR-mCherry fluorescence (middle, red), and anti-myc labeling for Rab 11 (right, 
magenta). 
 
Figure 3.13 Loss of channel recycling leads to accumulation of Kv1.5 in Rab 11 
positive endosomes. 
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Figure 3.14 Cartoon representation of the current running model for Kv1.5 trafficking 
in atrial myocytes. 
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CHAPTER 4  
 
DISCUSSION 
 
STRUCTURAL REQUIREMENTS FOR DRUG-INDUCED INTERNALIZATION 
 As described in chapter 2, we have reported a previously unrecognized 
mechanism of antiarrhythmic drug action in the acute modulation of Kv1.5 channel 
trafficking.
50
  Using quinidine, an antiarrhythmic agent which has both class Ia actions
140, 
141
 and class III actions in mammalian atrium and ventricle, we demonstrated that channel 
blockers can both inhibit ion conductance and regulate the stability of the channel protein 
within the membrane.  In this study, quinidine resulted in a dose- and time-dependent 
internalization of Kv1.5, concomitant with channel block.  Interestingly, this quinidine-
induced internalization of Kv1.5 was found to be subunit-dependent and stereospecific
50
 
which highlights the possibility for the development of atrial selective agents that 
specifically modulate surface density.  
Drug-induced internalization may occur for channel subunits selectively 
expressed in the atria.
50
  Quinidine exhibits promiscuous block of cardiovascular ion 
channels, including several members of the Kv channel family.  This lack of specificity  
 
Part of Chapter 4 is published as Schumacher SM, Martens JR. (2010). Ion channel 
trafficking: a new therapeutic horizon for atrial fibrillation. Heart Rhythm. 
Sep;7(9):1309-15.  For copyright release, please see Appendix I.   
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raised the question as to whether the drug-induced internalization was specific to Kv1.5 
or a general mechanism contributing to the block of current through multiple ion 
channels.  To address this specificity, we examined the effect of quinidine on two other 
prominent cardiovascular potassium channel subunits expressed endogenously in the 
human atrium and ventricle, Kv4.2 and Kv2.1.  Although ion permeability of both 
channels is blocked by quinidine (IC50 of 10 μmol/L and 20 μmol/L quinidine, 
respectively),
123, 124
 neither Kv4.2 nor Kv2.1 internalized in response to any drug 
concentration tested over the time course studied.  These studies have been expanded to 
include the Kv1.x family channel Kv1.4.  Although ion permeability of Kv1.4 is blocked 
by quinidine (IC50 of approximately 186 μmol/L),
186, 187
 Kv1.4 did not exhibit quinidine-
induced internalization, further supporting the subunit dependence of this drug action 
(Figure 4.1).  This subunit specificity may permit the development of drugs that avoid or 
reduce undesired proarrhythmic ventricular side effects.    
The potential to separate drug-induced channel internalization from pore block 
stimulates further interest in the design of drugs to modulate trafficking pathways. As 
discussed in chapter 2, within the Kv1.5 channel protein there is incomplete overlap in 
the binding sites required for quinidine-induced internalization and pore block.
50
  This 
was revealed through alanine-scanning mutagenesis of amino acid residues within the 
highly conserved drug binding site of Kv channels.
42, 129
  Previous studies had used 
alanine-scanning mutagenesis of the amino acids lining the ion conducting pore of Kv1.5 
to observe alterations in pore block by various antiarrhythmic compounds.
42, 46, 129, 188
  We 
chose to study the four single alanine mutant channels that exhibited the greatest 
reduction of pore block and showed that quinidine-induced internalization was abolished 
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with the T480A and I508A mutations.  In contrast, L510A and V512A underwent 
quinidine-induced internalization indistinguishable from wild-type.
42, 50, 129
  Expansion of 
these studies include four additional amino acids that demonstrated varying degrees of 
reduction of pore block.  These data revealed that I502A completely inhibited 
internalization, similar to T480A and I508A (Figure 4.2).  V505A exhibited partial 
inhibition of internalization, while similar to L510A and V512A, quinidine-induced 
internalization was not altered by the L506A or V516A mutations.  Interestingly P532L, 
a naturally occurring mutation (outside of the conserved drug binding site) in atrial 
fibrillation patients that results in a rightward shift in the dose response curve for 
quinidine block of channel current
130
 caused an equivalent (~10-fold shift in the EC50 
value) decrease in the sensitivity to quinidine-induced channel internalization.
50
 
Together, the fact that these mutations alter channel block and/or internalization of Kv1.5 
demonstrate that quinidine is inducing its effects through direct binding to the channel 
and not through off-target mediators of channel trafficking.   
The subunit dependence and incomplete overlap in amino acid requirements 
indicate that individual components of the Kv1.5 channel structure are critical for the 
quinidine-induced internalization.  However, additional studies of alanine-scanning 
mutants within the putative conserved drug-binding site are necessary to compare effects 
on surface density to those reported for pore block. Nevertheless, these data highlight the 
possibility for development of new agents that specifically enhance Kv1.5 channel 
internalization as an alternative and potentially beneficial new therapeutic strategy. A 
future goal of this study would be to elucidate the effect of these alanine mutations on 
pore block of Kv1.5 by quinidine compared to the other antiarrhythmic compounds 
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studied previously.  Correlative electrophysiological analysis and immunocytochemical 
studies would be performed to determine alterations in pore block and channel 
internalization in response to quinidine for each single alanine mutant of Kv1.5, 
quantifying any shift in the dose-response for quinidine or the extent of pore block and 
internalization.  This study would include an observation of any alterations in channel 
current kinetics or current density as a result of the alanine mutation.  Information 
obtained through these experiments would elucidate the amino acid components of the 
Kv1.5 channel that are necessary and/or sufficient for quinidine-induced internalization.  
Furthermore, these results would shed light on the potential separability of 
pharmacophores within the Kv1.5 pore region for pore block versus channel 
internalization, providing insight for future drug discovery or design. 
In order to develop new compounds that selectively modulate Kv1.5 surface 
density, the pharmacophore(s) responsible for pore block and internalization must be 
isolated (Figure 4.3).  The observation that quinine, a diastereomer of quinidine, blocks 
Kv1.5 current in a dose-dependent fashion without enhancing internalization, suggests 
that a highly stereospecific binding event is required to induce channel internalization, 
rather than some non-stereospecific interaction with the cell membrane.  Therefore, 
quinidine embodies structural features that enable it to induce endocytosis of Kv1.5.  The 
individual components of the quinidine structure critical for this stereospecific 
internalization/effect remain to be identified.  To initiate these studies we analyzed 
chloroquine, which maintains only the quinoline ring and tertiary amine of the quinidine 
structure.  While less potent and efficacious, this compound was able to enhance 
internalization of Kv1.5 above constitutive levels (EC50 = 8 M) (Figure 4.4).  These data 
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support the hypothesis of structural elements within quinidine that are both necessary and 
sufficient for the drug-mediated internalization.  Future studies would include correlative 
electrophysiological and immunofluorescence analysis of both pore block and channel 
internalization of Kv1.5 in response to a number of quinidine related and unrelated 
compounds to determine preliminary structure-activity relationships (SAR).  Studies 
would begin with the commercially available analogs of quinidine, including chloroquine 
and hydroquinidine for which studies are underway.  In addition, these studies would be 
expanded to modern, more clinically relevant antiarrhythmic drugs.  Structural features 
will be identified through the determination of SAR and then exploited in the design of 
novel chemical compounds with greater potency and selectivity for inducing endocytosis 
versus direct block of the channel.  
Initial SAR to identify individual components of the quinidine structure that are 
critical for inducing internalization through stereospecific binding will begin with 
potential binding components. The divergent positioning of the bicyclic aromatic and the 
bicyclic amine of quinidine and quinine suggest that both of these moieties may contain 
elements essential for channel internalization.  Binding components include the 
following: three hydrogen bond acceptors (aryl methoxy and two basic nitrogens), one 
hydrogen bond donor (OH), pi-stacking of the quinoline ring, and charge-charge 
interactions of the basic nitrogens with negatively charged residues.  The relative 
importance of these binding components for pore block and channel internalization will 
be evaluated through: removal of the aryl methoxy, replacement of the aryl methoxy with 
hydroxyl, replacement of the aliphatic hydroxyl with ketone, saturation of the vinyl 
group, acylation of the aliphatic and aromatic hydroxyl groups with various carboxylic 
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acids, and appending a hydroxyl group alpha to vinyl group.  Candidate compounds, 
including 16 commercially available analogs of quinidine that vary in the potential 
binding moieties noted, will be used to establish preliminary SAR.  Subsequent analogs 
will focus on further modification of those areas of the quinidine template that prove 
critical for inducing channel internalization to improve potency and selectivity. This may 
include the generation of synthetic analogs to incorporate additional esters of the aryl and 
aliphatic alcohols. The dose-dependence of internalization for each candidate analogs 
will be tested for Kv1.5 and other related Kv channels.  These experiments would be 
done in collaboration with Dr. Scott D. Larsen, Research Professor of Medicinal 
Chemistry and Co-Director of the Medicinal Chemistry Core Synthesis Laboratory 
(MCCSL) at the University of Michigan. 
Quinidine analogs examined must have sufficient membrane permeability to 
access the channel pore/active site and induce internalization.  As insufficient 
permeability would lead to the misinterpretation of negative data as a lack of intrinsic 
activity of the analog, the MCCSL has developed an in vitro assay for membrane 
permeability (PAMPA).
189
  This assay would be able to detect the membrane 
permeability of all quinidine analogs and synthetic compounds relative to the parent drug 
quinidine.  In the case that initial SAR does not provide guidance towards chemical 
components necessary for channel internalization as opposed to pore block, the scope of 
commercially available analogs could be broadened to include simpler compounds that 
contain only the quinoline or bicyclic amine components.  Evidence that such compounds 
may retain selective channel internalization was demonstrated through preliminary 
studies with chloroquine.  In addition, in collaboration with the Center for Chemical 
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Genomics (CCG) at the University of Michigan, we could develop and execute a high 
throughput assay based on Kv1.5-pHluorin that would interrogate a library of over 
150,000 compounds for the ability to induce endocytosis.  This strategy would provide 
the opportunity to identify leads divergent from quinidine-related compounds.  In chapter 
2, we observed that Kv1.5-pHluorin permits the real-time monitoring of cell surface 
channel protein. This was achieved through generation of a Kv1.5 channel construct in 
which the pH-sensitive GFP (pHluorin) was inserted into the extracellular S1-S2 loop.  
This GFP mutant displays variable fluorescence dependent upon the pH of the immediate 
environment.  Cell surface Kv1.5-pHluorin fluoresces strongly at pH 7.4, however 
internalization of channel into acidified intracellular vesicles at pH 5.0-5.5 quenches 
fluorescence providing a live read-out of channel endocytosis in response to specific 
stimuli and independent of antibody labeling.
190
  The generation of HL-1 cells stably 
expressing Kv1.5-pHluorin allows the application of this technology to high-throughput 
measurements of quinidine analogs.   
To date, there is no crystal structure for Kv1.5; however, the crystal structure for 
the transmembrane domains of the related Kv1.2 channel has been elucidated.  Molecular 
modeling of the Kv1.5 pore/active site will be undertaken using homology models based 
on Kv1.2 crystal structure. Data from our alanine-scanning mutagenesis studies of the 
amino acid requirements within the channel pore, as well as our preliminary SAR of the 
chemical structure of the drug molecule would be used to further validate or refine the 
model of the Kv1.5 pore region and drug-binding site.  This model would then be used to 
dock quinidine related and unrelated compounds and guide the study towards compounds 
that would promote Kv1.5 internalization without pore block, focusing on analogs from 
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commercially available compound collections containing the minimized structural 
components of quinidine.  In addition to guiding additional SAR targets, creation of a 
valid binding model will permit the incorporation of structure based drug design (SBDD) 
for compounds that would display selectivity and efficacy for Kv1.5 channel 
internalization.  Testing will be facilitated by high-throughput assays using HL-1 cells 
stably expressing Kv1.5-pHluorin. Again, these studies will be done in collaboration with 
Dr. Larsen who has extensive experience with SBDD, and the MCCSL has the resources 
to dock and score candidate targets prior to ordering of compounds. Promising 
compounds identified would be tested in native myocytes by recording IKur function in 
the presence and absence of calcium-chelators. The end goal of these studies would be to 
discover a compound that could selectively induce internalization of Kv1.5 without 
inducing pore block in order to exhibit ventricular sparing clinical efficacy and safety in 
the treatment of atrial fibrillation in clinical trials.     
Another important therapeutic aspect of quinidine-induced internalization of 
Kv1.5 is that it is acute and reversible, further suggesting that it may be effective for 
acute cardioversion.  In our study we found that the quinidine-induced internalization was 
rapid, reaching a plateau within 10 minutes.  Combined with the fact that this drug-
mediated trafficking effect occurred at resting membrane potential in our 
immunocytochemical assays, these data indicate that the rate-limiting factor for this 
effect is likely equilibration of drug across the membrane. Importantly, upon drug 
washout the quinidine-induced internalized Kv1.5 recycled back to the plasma membrane 
at a rate indistinguishable from constitutive channel recycling.  Thus, the quinidine-
mediated trafficking effect results in an acute increase in channel endocytosis, 
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specifically, without altering the endogenous recycling of Kv1.5.  If a drug were designed 
to specifically modulate Kv1.5 channel trafficking it could, in theory, be used to cause a 
rapid internalization of channel with recovery after drug withdrawal.  Therefore, acute 
modulation of ion channel surface levels may offer the selective advantage for a rapid, 
reversible decrease in IKur with a subsequent increase in action potential duration that may 
terminate acute onset of AF without altering the overall pool of Kv1.5 channel.  In 
contrast, we found that chronic treatment with quinidine diverted Kv1.5 channel to the 
proteasomal degradation pathway.   It is unclear if this chronic decrease in surface 
expression is advantageous or an unwanted side-effect of the long-term drug treatment. 
For instance, the time course of recovery from this repression may precipitate drug-
withdrawal side effects.  Furthermore, long-term suppression of channel expression may 
contribute to remodeling of heart tissue in which a decrease in Kv1.5 channel protein 
levels has already been documented.  The alternative is that this chronic suppression of 
Kv1.5 channel protein levels may overcome the current limitations of acute cardioversion 
which fails to terminate breakthrough AF or adequately subdue the arrhythmogenic 
substrate and may result in the benefit of maintained rhythm control.  
An important finding that goes beyond the therapeutic potential of this approach 
is that the drug-induced trafficking effect is calcium-dependent and raises significant 
issues for drug safety screening.
50
  The calcium-dependent trafficking component was 
responsible for a 3-fold shift in the dose response for quinidine and is therefore critically 
important when considering the in vivo effects of this drug and likely many others. It has 
been well established that non-antiarrhythmic drugs can have proarrhythmic effects 
through off target inhibition of cardiovascular ion channel currents. This has been 
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reported for psychiatric drugs, antihistamines, antimicrobials and other compounds, many 
of which can induce QT prolongation with subsequent risk of torsade de pointes.
191
  As a 
result, pharmaceutical companies and regulatory agencies mandate that cardiac ion 
channel testing be part of the drug safety profiling of all new compounds. Current drug 
safety profiling is almost entirely focused on a drug’s capacity to block ion conduction.  
This is commonly tested through electrophysiological measurement of current in the 
presence or absence of drug, using a calcium chelating agent to isolate the drug-channel 
interaction. Therefore antiarrhythmic, and non-antiarrhythmic, compounds that alter ion 
channel trafficking may show greater efficacy and potency in vivo than can be predicted 
by current drug safety profiling.  This may result in a dramatic underestimation of the 
desired clinical effect and/or undesired side effects of a drug.  
 The results discussed here highlight the potential for development of new agents 
that selectively modulate ion conduction and/or the stability of channel protein in the 
membrane.  In addition, manipulation of the trafficking of functional membrane channel 
may provide an avenue for developing new therapies with atrial selectivity and clinical 
efficacy and safety for the treatment of AF and potentially other cardiovascular 
arrhythmias.  
 
ACCESSORY SUBUNITS 
In the human heart Kv channels are composed of four alpha subunits arranged as 
homo or heterotetramers that may associate with one or more auxiliary beta subunits to 
form the functional ion channel in the plasma membrane.  Association with Kv beta 
subunits has been shown to alter both the cell surface expression and kinetics of Kv 
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current.
88, 92, 93, 192-202
  It is the combination of alpha and beta subunits in the membrane 
that ultimately defines the biological and pharmacological activity of channels in vivo.  In 
particular, specific alteration of Kv1.5 upon association with hKvBeta1.3 and 
hKvBeta2.1 has been shown.
88, 92, 203
  We therefore extended our study to include an 
investigation of the effects of these auxiliary beta subunits on the mechanism and 
regulation of endogenous and quinidine-induced internalization of Kv1.5.  In our system 
hKvBeta1.3 alters Kv1.5 current kinetics as shown in the previous literature (Figure 4.5).  
Electrophysiological analysis of Kv1.5 current kinetics upon functional association of 
Kv1.5 with hKvBeta2.1 will also be performed.  Unlike hKvBeta2.1, co-expression with 
hKvBeta1.3 significantly decreased cell surface levels of Kv1.5 (Figure 4.6).  As this 
may occur through a decrease in anterograde delivery of newly synthesized channel, 
increase in endocytosis, or decrease in channel recycling, future studies will investigate 
the underlying mechanism of this decrease.  Preliminary data show that while 
hKvBeta1.3 does not alter the rate of constitutive internalization of Kv1.5, both 
hKvBeta1.3 and hKvBeta2.1 alter the rate of channel recycling (Figure 4.7).  Future 
studies will determine the amount of total recycled channel as well and further elucidate 
the mechanisms by which hKvBeta1.3 and hKvBeta2.1 are altering Kv1.5 surface density 
and trafficking.  Importantly, quinidine-induced internalization of Kv1.5 was completely 
blocked by co-expression with either hKvBeta1.3 or hKvBeta2.1 (Figure 4.8).   
It has been previously shown that hKvBeta1.3 contains and N-terminal “ball and 
chain” motif which rapidly inactivates Kv1.5 current by blocking the cytosolic pore of 
the channel.
93
  More importantly, it has been shown that this interaction of hKvBeta1.3 
can alter drug binding to Kv1.5 due to a competition for the conserved drug binding site 
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in the channel pore.
89, 93, 204, 205
  Therefore we hypothesized that the mechanism by which 
hKvBeta1.3 inhibited quinidine-induced internalization of Kv1.5 was through a loss 
quinidine binding to the channel pore.  This hypothesis was supported by the shift in the 
IC50 of quinidine for Kv1.5 from 6.2 µM to 49.9 µM as demonstrated by Gonzalez et al.
89
  
To confirm this hypothesis, we chose to study the Kv1.5-V512A mutant discussed above, 
which we have shown does not alter the quinidine-induced internalization of Kv1.5.  
Decher et al. demonstrated that KvBeta1.3 was not able to induce rapid inactivation of 
Kv1.5-V512A, suggesting a disruption in association of the N-terminal inactivation 
domain of hKvBeta1.3 with the cytosolic pore of Kv1.5.
204
  We found that this single 
point mutation completely restored the quinidine-induced internalization of Kv1.5 in the 
presence of hKvBeta1.3 (Figure 4.9).  Unlike hKvBeta1.3, hKvBeta2.1 does not contain 
the N-terminal inactivation domain and does not confer rapid inactivation to non-
inactivating Kv alpha subunits.  Therefore, a future goal of this study will be to 
investigate the mechanisms by which hKvBeta2.1 inhibits the quinidine-induced 
internalization of Kv1.5, which may occur through specific protein-protein interactions or 
post-translational modification of the beta subunit.  In addition, hKvBeta1.2 expression 
has been demonstrated in human atria and ventricles,
195, 199
 and hKvBeta1.2 co-
expression has been shown to alter Kv1.5 current kinetics.  Future studies will also 
include an investigation of the effect of hKvBeta1.2 co-expression on quinidine-induced 
internalization in cardiomyocytes.   
Kv channels are expressed as homo and heterotetramers.  The majority of 
investigations into the existence and subunit stoichiometry of these heteroterameric 
populations have focused on neuronal tissues in the central nervous system.  
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Electrophysiological studies have revealed that native K
+
 currents in the cardiovascular 
system cannot be fully reconstituted by expression of single cloned Kv alpha subunits in 
heterologous systems.
206
  While several effectors may contribute to this disparity, 
heterotetrameric channel assembly cannot be ruled out.  Our lab has recently developed a 
bimolecular fluorescence complementation (BiFC) technique to visualize 
heterotetrameric channel populations and their regulation.
207
  This technique employs the 
insertion of either half of a split fluorescent molecule into the extracellular loop of a Kv 
channel alpha subunit.  Co-translational association of the alpha subunits allows 
formation of the complete fluorophore and restores fluorescence, demonstrating 
expressing of the heterotetramer.  Live-cell labeling with antibodies against the 
fluorescent molecules and electrophysiological analysis then reveal the cell surface 
expression of functional heterotetrameric channels.  Future studies will utilize this 
technique to study the formation of heterotetrameric channels within cardiovascular Kv 
channel subunits.  Specifically they will investigate the effects of subunit assembly on the 
current kinetics, constitutive trafficking, and sensitivity of Kv1.5 to quinidine-mediated 
pore block and channel internalization.           
 The composition of Kv channels in the membrane determines their activity in 
vivo.  Therefore, knowledge of the interaction of alpha and beta subunits, and the effect 
of these associations on channel function and pharmacological activity, is important for 
our understanding not only of normal physiology, but pathophysiology and therapeutics.  
Shown here, association of Kv1.5 with the accessory subunits hKvBeta1.3 and 
hKvBeta2.1 blocked quinidine-induced internalization of Kv1.5.  Given the distribution 
of hKvBeta1.3, which is more highly expressed in the ventricles than atria,
195
 and the co-
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localization of Kv1.5 with hKvBeta2.1 in the vasculature,
208-211
 this association with 
Kv1.5 may provide additional tissue specificity for the quinidine-induced internalization 
of Kv1.5.  For instance, hKvBeta subunit association may block non-specific, off-target 
effects of drug-mediated internalization of Kv1.5, while allowing for the desired effect in 
reducing Kv1.5 encoded IKur in the atria.  This tissue specificity may provide additional 
clinical efficacy and safety in the development of compounds for Kv1.5 internalization as 
a therapeutic avenue for the treatment of atrial fibrillation. 
 
MOLECULAR MOTORS AND ADAPTORS 
 Previously, our lab has demonstrated a role for the dynein retrograde motor 
complex in the constitutive internalization of Kv1.5.
111
  In addition, we demonstrated a 
role for the Rab GTPases Rab 4 and Rab 11, but not Rab 5 or Rab 8, in the post-
endocytic recycling of Kv1.5.  In agreement with our studies, work from the lab of Dr. 
Fedida has independently described a role for the dynein motor complex and Rabs 4 and 
11 in the trafficking of Kv1.5; however, in contrast, their work did indicate a role for Rab 
5.
112, 212
  This may represent a difference in the cell lines used (HL-1 mouse atrial 
myocytes versus HEK293 cells and H9c2 rat cardiac myoblasts) or the experimental 
design used to observe alterations in cell surface Kv1.5.  In chapter 3 we describe 
involvement of the unconventional myosin V motor isoforms in the cell surface 
trafficking of Kv1.5.  Myosin Va facilitates anterograde delivery of Kv1.5 to the plasma 
membrane, whereas myosin Vb mediates the post-endocytic recycling of Kv1.5 through 
coupling to Rab 11, providing a mechanistic link to our previous data demonstrating a 
role for Rab 11.  This direct coupling of myosin Vb to Rab 11 for channel recycling was 
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revealed through the use of a myosin Vb mutant YE/QR that is unable to bind Rab 11.  In 
addition, the decrease in cell surface Kv1.5 by co-expression with myosin Vb YE/QR, 
was not altered by co-expression with the constitutively active (CA) Rab 11 construct, 
further supporting this mechanism of Kv1.5 channel recycling.  Selectivity was 
demonstrated through the use of a myosin Vb mutant QL/YC that is unable to bind Rab 
8.  In agreement with our previous publication in which Rab 8 was not important for 
Kv1.5 trafficking, we found no alteration in steady-state cell surface levels or recycling 
of Kv1.5 upon co-expression with myosin Vb QL/YC.   
 Kv1.5 channel trafficking by myosin Va and myosin Vb occurred along actin 
filaments in the periphery of the cell.  Cell surface trafficking of membrane proteins is 
believed to be the result of both short-range trafficking along actin filaments in the cell 
periphery and long-range trafficking along microtubules to the periphery of the cell.  As 
mentioned, constitutive internalization of Kv1.5 occurs via trafficking along microtubules 
by the dynein retrograde motor complex.  It remains to be elucidated, however, whether 
microtubule based trafficking events participate in the anterograde delivery of newly 
synthesized Kv1.5 to the plasma membrane or in the recycling of Kv1.5 from perinuclear 
endosomal populations back to the plasma membrane.  It will also be important to 
identify the molecular motors and adaptors that underlie these trafficking steps.  Data 
from Zadeh et al. indicate a role for the kinesin-1 isoform Kif5b in the post-Golgi, pre-
endocytic anterograde trafficking of newly synthesized Kv1.5 to the plasma 
membrane.
150
  Published and preliminary data from our lab suggest the involvement of 
Kif17 and KifC3 in Kv1.5 trafficking events based on a reduction in steady-state cell 
surface levels of Kv1.5 in response to co-expression with dominant-negative (DN) forms 
116 
 
of these motor proteins.
149
  The precise role of these molecular motors in the trafficking 
of Kv1.5, as well as the mechanism and adaptor proteins underlying this role, remain to 
be elucidated. 
 In addition to elucidating the molecular machinery and adaptor proteins involved 
in the trafficking of Kv1.5, it is important to identify any specificity within these 
trafficking mechanisms.  For instance, in chapter 3 we found that co-expression with 
myosin Va and myosin Vb DN did not alter the cell surface levels of the hERG potassium 
channel.  In addition, we demonstrate a role for dynamin in the internalization of Kv1.5 
that can be enhanced by overexpression of wild-type dynamin 1 and significantly 
abrogated by the DN form of dynamin 1, dynamin S61D.  In contrast to this clear role in 
the internalization of Kv1.5, we have data demonstrating no effect of dynamin S61D on 
the steady-state cell surface levels of Kv1.4.  Internalization of Kv1.4 is blocked by co-
incubation with myristoylated dynamin inhibitory peptide (DIP);
213
 however, this 
compound does not distinguish between dynamin 1, 2, or 3.  These data suggest that cell 
surface trafficking of membrane ion channels may not occur via a conserved mechanism, 
but may involve varying degrees of specificity in the molecular machinery or pathways 
utilized.  This specificity may provide additional therapeutic targets and avenues for the 
treatment of various cardiovascular arrhythmias and thereby warrant special attention.   
CONCLUSION 
 Through the work of this thesis, we revealed pleiotropic effects of the 
antiarrhythmic drug quinidine on Kv1.5, which encodes the major repolarizing current 
IKur in the human atria.  We characterized quinidine-induced internalization of Kv1.5, in 
addition to pore block, that was significantly greater than constitutive endocytosis and 
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exhibited both subunit-dependence and stereospecificity.  Furthermore, drug-mediated 
internalization was conserved in dissociated neonatal mouse cardiomyocytes. In addition, 
drug-mediated internalization was calcium dependent, and therefore not observed under 
experimental conditions including a calcium chelating agent, as used in classic 
electrophysiological analysis.  Chronic treatment with a clinically relevant dose of 
quinidine led to channel degradation, with implications for therapeutic and/or withdrawal 
effects.  While the mechanism for calcium-dependent internalization remains to be 
determined, these data demonstrate a potential new therapeutic avenue for the selective 
inhibition of Kv1.5 in order to attain atrial selectivity as well as clinical safety and 
efficacy for the treatment of atrial fibrillation. 
 We showed that the unconventional myosin V motor isoforms myosin Va and Vb 
play an important role in the delivery and cell surface levels of Kv1.5 in cardiomyocytes.  
The role of myosin Va and Vb in determining surface Kv1.5 effected alterations in IKur 
current in adult rat cardiomyocytes.  A level of subunit specificity was observed in that 
myosin Va and Vb did not play a role in determining the cell surface levels of the hERG 
potassium channel.  We demonstrated that myosin Va acts upstream of internalization 
during delivery of newly synthesized Kv1.5 to the plasma membrane.  Myosin Vb is 
involved in the post-endocytic trafficking of Kv1.5 through recycling endosomes back to 
the plasma membrane.  Coupling of myosin Vb to the Rab GTPase Rab 11 was necessary 
for this channel recycling.  While there are several steps in the trafficking pathway for 
which the molecular motors and adaptors remain to be elucidated, these data provide 
some insight into the mechanisms of ion channel trafficking in the cardiovascular system.  
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Importantly, selective myosin Vb-mediated recycling of Kv1.5 could serve as novel 
therapeutic target for the treatment of atrial fibrillation. 
 These findings are significant since they represent new potential therapeutic 
avenues for the treatment of atrial fibrillation.  Selective quinidine-induced 
internalization of Kv1.5 highlights the potential for the development of new compounds 
that alter the functional ion channel density in the membrane as a means to alter 
cardiovascular excitability.  These data also raise questions regarding the current methods 
of drug safety screening as well as the role of internalization in the therapeutic and 
withdrawal effects of current antiarrhythmic therapy.  We also demonstrate selectivity in 
the molecular machinery underlying cardiovascular ion channel trafficking, with 
therapeutic potential in the modulation of channel recycling.  Continued elucidation of 
the molecular machinery involved in cardiovascular ion channel trafficking could reveal 
novel therapeutic targets and strategies for the regulation of surface channel densities in 
the treatment of cardiovascular arrhythmias. 
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Figure 4.1 Quinidine-induced internalization is subunit-dependent.  
 
Dose–response of internalization for HL-1 cells expressing Kv1.4-GFP treated with 
increasing concentrations of quinidine for 10 minutes at 37°C. ***p<0.001 as determined 
by 1-way ANOVA with Tukey post test.  
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Figure 4.2 Structural requirements for quinidine binding are partially conserved for 
pore block and channel internalization.  
 
Quinidine-induced internalization for HL-1 cells expressing Kv1.5-GFP containing the 
T480A, I502A, V505A, L506A, I508A, L510A, V512A, or V516 mutation treated with 
100 µmol/L quinidine for 10 minutes at 37°C. **p<0.01, ***p<0.001 as determined by 
1-way ANOVA with Tukey post test. 
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Figure 4.3 Strategies to isolate drug-induced internalization from pore block.  
 
Cartoon representation of the potential drug binding site of the Kv1.5 channel pore. (1) 
Ion channel mutagenesis can be used to fully characterize the incomplete overlap in the 
drug binding site for pore block and channel internalization. (2) Multiple moieties within 
the quinidine molecule can be studied in structure activity analysis to identify the 
pharmacophore for drug-induced internalization. 
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Figure 4.4 Chloroquine stimulates internalization of Kv1.5 in a dose-dependent 
manner. 
 
Dose–response of internalization for HL-1 cells expressing Kv1.5-GFP treated with 
increasing concentrations of quinidine or chloroquine for 10 minutes at 37°C. **p<0.01, 
***p<0.001 as determined by 1-way ANOVA with Tukey post test.  
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Figure 4.5 hKvβ1.3 induces rapid inactivation of Kv1.5 channel current. 
 
Electrophysiological recordings from HL-1 cells transiently expressing either Kv1.5-GFP 
and DsRed (left traces) or Kv1.5-GFP and hKvβ1.3 (right traces). Cells were maintained 
at -80 mV followed by 250 ms pulses applied in 10 mV steps from -80 mV to +60 mV. 
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Figure 4.6 hKvβ1.3, but not hKvβ2.1, decreases steady-state cell surface levels of 
Kv1.5. 
 
Quantification of surface channel in HL-1 cells expressing Kv1.5-GFP and DsRed, 
hKvβ1.3, or hKvβ2.1.  Scale bars, 10 μm. ***p<0.001 as determined by 1-way ANOVA 
with Tukey post test. 
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Figure 4.7 hKvβ1.3 alters constitutive internalization, and hKvβ2.1 alters constitutive 
internalization and recycling of Kv1.5. 
 
(A) Quantification of internalized channel in HL-1 cells expressing Kv1.5-GFP and 
DsRed, hKvβ1.3, or hKvβ2.1 in response to 0, 5, 10, 15, 20, 30, or 60 min at 37°C. (B) 
Quantification of recycled channel in HL-1 cells expressing Kv1.5-GFP and DsRed, 
hKvβ1.3, or hKvβ2.1 in response to 0, 10, 20, 30, 60, and 120 min at 37°C. Beta subunit 
was detected by mouse anti-c-myc followed by goat anti-mouse Alexa Fluor 594. Below 
each bar graph are representative images for that condition. *** indicates p < 0.001 as 
determined by one way ANOVA with Tukey post-test.  
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Figure 4.8 Quinidine-induced internalization of Kv1.5 is blocked by co-expression 
with hKvβ1.3 and hKvβ2.1. 
 
Quantification of internalized channel in HL-1 cells expressing Kv1.5-GFP and DsRed, 
Kvβ1.3, or Kvβ2.1 following a 10-min incubation at 37 °C with vehicle (0.1% DMSO) or 
100 μmol/L quinidine. Beta subunit was detected by mouse anti-c-myc followed by goat 
anti-mouse Alexa Fluor 594. Below each bar graph are representative images for that 
condition. Scale bars=10 μm. ***P<0.001 as determined by one-way ANOVA with 
Tukey post test. 
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Figure 4.9 The V512A mutation of Kv1.5 restores quinidine-induced internalization 
in the presence of hKvβ1.3. 
 
Quantification of internalized channel in HL-1 cells expressing Kv1.5-GFP and DsRed or 
Kvβ1.3, or Kv1.5_V512A_GFP and DsRed or hKvβ1.3 following a 10-min incubation at 
37 °C with vehicle (0.1% DMSO) or 100 μmol/L quinidine allowing for internalization. 
Beta subunit was detected by mouse anti-c-myc followed by goat anti-mouse Alexa Fluor 
594. ***P<0.001 as determined by one-way ANOVA with Tukey post test. 
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